var title_f21_46_22240="Hydrocarbon aspiration radiogragh";
var content_f21_46_22240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hydrocarbon aspiration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This child developed right middle lobe and bilateral lower lobe infiltrates within hours of aspiration of paint thinner.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patricia Primm, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_46_22240=[""].join("\n");
var outline_f21_46_22240=null;
var title_f21_46_22241="Vulvar abscess";
var content_f21_46_22241=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This diabetic woman has a left vulvar abscess involving the labium majus. Note the increased size when compared with the right labium. There is also a background of erythema about the vulva and perianal area from chronic superficial candidiasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andrea R Thurman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_46_22241=[""].join("\n");
var outline_f21_46_22241=null;
var title_f21_46_22242="Nail plate post-surgery 2";
var content_f21_46_22242=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Replacement of a partially avulsed nail plate after surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After partial avulsion, the nail plate is put back in place and secured with Steri-strips.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Rich P. Nail surgery. In: Dermatology, 3rd ed, Bolognia JL, Jorizzo JL, Schaffer JV (Eds), Elsevier 2012. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_46_22242=[""].join("\n");
var outline_f21_46_22242=null;
var title_f21_46_22243="Digital angiogram in MCTD";
var content_f21_46_22243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Digital angiogram in mixed connective tissue disease (MCTD) vasculopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 303px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Digital angiogram in a patient with mixed connective tissue disease shows an attenuated distal ulnar artery (arrow), absence of the deep palmar arch, and absence or compromise of several digital arteries including that to the fifth digit. Such medium-sized arterial disease is common in this disorder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert M Bennett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_46_22243=[""].join("\n");
var outline_f21_46_22243=null;
var title_f21_46_22244="Retaining ovary at hysterectomy";
var content_f21_46_22244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hysterectomy without oophorectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clamp placement when the ovaries are to be retained.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_46_22244=[""].join("\n");
var outline_f21_46_22244=null;
var title_f21_46_22245="Air exchange lungs PI";
var content_f21_46_22245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F73121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F73121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    How air is exchanged in the lungs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 443px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts how oxygen (02) and carbon dioxide (CO2) pass between the alveloi (inside the lung) and the capillaries (the blood stream).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anatomical Chart Co. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_46_22245=[""].join("\n");
var outline_f21_46_22245=null;
var title_f21_46_22246="Midline incision of the abdominal wall";
var content_f21_46_22246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Midline incision of the abdominal wall",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The linea alba is incised and muscles separated in the midline. The peritoneum is opened at the cephalic pole of the incision. The peritoneal incision is expanded longitudinally, slightly off midline to avoid the urachus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_46_22246=[""].join("\n");
var outline_f21_46_22246=null;
var title_f21_46_22247="Identifying and managing casualties of biological terrorism";
var content_f21_46_22247=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Identifying and managing casualties of biological terrorism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/46/22247/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/46/22247/contributors\">",
"     Cameron Wolfe, MBBS (Hons)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/46/22247/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/46/22247/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/46/22247/contributors\">",
"     Richard D Zane, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/46/22247/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/46/22247/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/46/22247/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H16715219\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Terrorism can come in many forms. Biological events have the potential to be more readily disseminated and destructive than chemical or nuclear weapons [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/1\">",
"     1",
"    </a>",
"    ]. Lethal amounts of biological agents are relatively easy to manufacture, conceal, transport, and release. The United States Congressional Office of Technology Assessment has estimated that a 100 kg payload of aerosolized anthrax spores, if released upwind of Washington, DC, could result in 130,000 to 3 million deaths, matching the lethality of the hydrogen bomb [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with emerging infectious diseases, detection and control of biological attacks depend upon a strong and flexible public health system at the local, state and federal levels. Additionally, well-trained and vigilant front line health professionals are required, especially in detecting covert biological attacks. Primary healthcare providers may be the first to observe and report any unusual illness patterns in the event of such an attack.",
"   </p>",
"   <p>",
"    This topic will address the history of bioterrorism, the organisms of greatest concern, and the immediate management of persons with possible exposure. Treatment of established infections, such as anthrax, is discussed within the separate disease topics within this program. Chemical terrorism is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8521?source=see_link\">",
"     \"Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16715226\">",
"    <span class=\"h1\">",
"     HISTORY OF BIOLOGICAL WEAPONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The greatest advancements in biological weapons occurred in the twentieth century. Attacks have been targeted at both animals and humans [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/3\">",
"     3",
"    </a>",
"    ], and have been perpetrated by multiple nations. &nbsp;",
"   </p>",
"   <p>",
"    The first attempts at restricting the proliferation of biological capacity occurred with the 1925 Geneva Protocol for the &ldquo;Prohibition of the Use in War of Asphyxiating, Poisonous or Other Gases, and of Biological Methods of Warfare&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/1\">",
"     1",
"    </a>",
"    ]. However, even after ratification, most countries continued to develop their biologic capacity. The United States built an offensive weapons program at Camp Detrick in 1942 and continued to develop technology in this area, fueled by the ensuing Cold War [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/4\">",
"     4",
"    </a>",
"    ]. A multilateral treaty finally formed in 1972, signed by 140 countries.",
"   </p>",
"   <p>",
"    However, there was evidence of ongoing use of biologic weapons in other countries, such as Iraq and the former Soviet Union [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The accidental release of aerosolized anthrax spores from a Soviet weapons plant in Sverdlovsk resulted in the deaths of at least 68 people from inhalation anthrax [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16715233\">",
"    <span class=\"h1\">",
"     EVIDENCE OF PRIOR BIOTERRORISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Terrorist groups and religious cults have also employed biological agents worldwide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1211773\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, there have been several instances of biologic terrorism over the past decade including the following events:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 1984, a religious cult intentionally infected restaurant salad bars in Oregon with salmonella, resulting in disease amongst 751 people; this episode revealed the vulnerability of the food and water supply [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=see_link\">",
"       \"Microbiology and epidemiology of salmonellosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In 2001, 22 people in the United States developed inhalational or cutaneous anthrax when this biological agent was sent through the mail to multiple states, resulting in five deaths [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7224?source=see_link\">",
"       \"Clinical manifestations and diagnosis of anthrax\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In 2003, an envelope with a threatening note and a sealed container containing ricin was processed at a mail processing and distribution facility in South Carolina [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/10\">",
"       10",
"      </a>",
"      ]. An investigation by the Centers for Disease Control (CDC) found no evidence of environmental contamination and no cases of ricin-associated illness. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The United States also has a number of BioSafety Level (BSL) 3 and 4 laboratories spread across the country. A hurricane, or similar natural disaster, if located near such a facility, could theoretically result in an accidental release of organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1211780\">",
"    <span class=\"h2\">",
"     Worldwide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Japanese cult, Aum Shinrykio, used sarin nerve gas for its attack on the Tokyo subway resulting in over 6000 casualties and 12 deaths in 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/12\">",
"     12",
"    </a>",
"    ]. The group also attempted to disperse anthrax and botulism on at least eight occasions; these attacks were associated with no known illness. Other groups who have reportedly used biological weapons include the Viet Cong, who used focally contaminated spears during the Vietnam War, and the Mau Mau rebels in Kenya, who used plant latex toxins to kill cattle [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20472916\">",
"    <span class=\"h1\">",
"     THE ROLE OF REGULATORY AGENCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC has been designated by the United States Department of Health and Human Services to coordinate and lead the planning efforts to upgrade national public health capabilities at the local, state, and federal level. Liaison channels now also exist between the CDC, the Federal Bureau of Investigation (FBI), and Federal Emergency Management Agency (FEMA) in order to better coordinate responses of national relevance. The FBI has jurisdiction over a bioterrorism response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1212247\">",
"    <span class=\"h1\">",
"     DETECTION OF BIOLOGIC EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of biological agents can be difficult since biological events are frequently invisible and lead to slow accumulation of casualties, in contrast to chemical spills, which often lead to rapid casualties. The appropriate responses to a potential bioterrorism event include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surveillance, detection and containment",
"     </li>",
"     <li>",
"      Confirmation and case detection",
"     </li>",
"     <li>",
"      Directed prophylaxis as required for possible exposure",
"     </li>",
"     <li>",
"      Directed therapy as required for possible or confirmed disease",
"     </li>",
"     <li>",
"      Clean up",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      epidemiological investigation as necessary",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20472890\">",
"    <span class=\"h1\">",
"     THE ROLE OF THE CLINICIAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary health care providers, emergency department physicians, intensivists, infection control practitioners, and infectious disease physicians may be the first persons to recognize disease caused by a variety of biological agents, including pathogens that are infrequently seen. Clinicians must remain mindful that an outbreak of disease might be the result of an intentional exposure. Bioterrorism may be suspected when unusually high rates of a single illness are seen, or an unusual pathogen is isolated in the laboratory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16715254\">",
"    <span class=\"h1\">",
"     SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective surveillance systems for detection of biological outbreaks need to include real time data from emergency rooms, laboratories, pharmacies and even schools to identify patterns of illness. These early responses are important for timely distribution of prophylactic medications or vaccines. The CDC can often deploy a specialized epidemiological and laboratory response team to assist in the investigations of unexplained or suspicious outbreaks at the request of state health departments, or if federally mandated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16715261\">",
"    <span class=\"h1\">",
"     PUBLIC HEALTH RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the event of a possible terrorist event, local emergency response systems should be activated by dialing 911 in the United States, or equivalent emergency telephone numbers in other countries. In communities without 911 systems, local law enforcement officials should be notified. The local FBI office and local and state public health authorities should also be notified, who will notify federal agencies if required. &nbsp;",
"   </p>",
"   <p>",
"    In the United States, a number of prominent academic centers have created Preparedness and Emergency Response Research Centers (PERRCs) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/14\">",
"     14",
"    </a>",
"    ]. These centers act as coordinating points to improve cooperation between public health and emergency medical systems. &nbsp;",
"   </p>",
"   <p>",
"    The public health response to bioterrorism also requires effective communication and coordination with first responders and law enforcement officials. Public messaging through the general media can alert the wider community. Collaboration between the media and public health agencies has occurred during prior major outbreaks in the United States (ie, anthrax and pandemic influenza).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20472973\">",
"    <span class=\"h1\">",
"     ORGANISMS OF CONCERN",
"    </span>",
"   </p>",
"   <p>",
"    The CDC has identified a number of pathogens that could be used in biological terrorism and have ranked them into various categories based on their overall potential to cause harm (",
"    <a class=\"graphic graphic_table graphicRef79744 \" href=\"UTD.htm?36/15/37116\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. High-priority agents include organisms that:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Can be easily disseminated or transmitted person-to-person",
"     </li>",
"     <li>",
"      Cause high mortality",
"     </li>",
"     <li>",
"      Might cause public panic and social disruption",
"     </li>",
"     <li>",
"      Require special action for public health preparedness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The highest priority agents (Category A) include anthrax and smallpox. These agents are of particular concern because they can be grown easily in large quantities and are sturdy organisms, resistant to destruction. They are also particularly well suited to airborne dissemination, thereby infecting large numbers of people. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35797?source=see_link\">",
"     \"The epidemiology, pathogenesis, and clinical manifestations of smallpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39079?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of anthrax\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second highest priority agents (Category B) include those that are moderately easy to spread, and generally cause less morbidity and mortality than Category A, but may require enhanced diagnostic capacity or surveillance techniques. Examples include agents of Q fever or brucellosis.",
"   </p>",
"   <p>",
"    Category C agents include pathogens that could be engineered for mass dissemination either because of ready availability, or ease of production and transport. They are usually agents of significant potential morbidity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mortality. Examples include hantavirus or multidrug-resistant tuberculosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5382341\">",
"    <span class=\"h1\">",
"     TOXINS OF CONCERN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ricin, listed as a Category B agent, is a toxin naturally found in castor beans. The clinical manifestations of ricin poisoning differ by route of exposure. Inhalational ricin may cause respiratory distress, fever, cough and pulmonary edema. Effects of this toxin may occur within eight hours of inhalation. Ingestion of ricin can lead to symptoms of vomiting, bloody diarrhea and dehydration within six hours. In severe cases, multi-organ failure can occur.",
"   </p>",
"   <p>",
"    There is no proven antidote; supportive care and possible gastric lavage and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    can be considered. Decontamination procedures should be undertaken for skin or clothing contamination since ricin can also cause burns.",
"   </p>",
"   <p>",
"    Trichothecene mycotoxins, derived from fungi, have also been used in aerosolized or powdered formulations for bioterrorism. These mycotoxins can lead to minor symptoms such as contact pruritis, burning, or blistering to severe symptoms such as vomiting and ataxia with hypotension and coagulopathy. Inhalation or ingestion are more likely to cause systemic effects than cutaneous exposures. No vaccine or chemoprophylactic agents exist.",
"   </p>",
"   <p>",
"    If ricin or mycotoxin exposure is suspected, the Centers for Disease Control (CDC) should be contacted for assistance, including diagnosis. Early consideration of toxin exposure is needed for appropriate decontamination procedures and supportive care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16715268\">",
"    <span class=\"h1\">",
"     CONFIRMATION AND DIAGNOSTIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a potential bioterrorist event has been suspected or detected, the etiologic agent must be confirmed. &nbsp;",
"   </p>",
"   <p>",
"    As part of the national preparedness effort, a network of laboratories that communicate directly with the public health infrastructure has been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/17\">",
"     17",
"    </a>",
"    ]. Similar moves in the European Union plan to link all major biosafety laboratories together to enable a more effective response [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/18\">",
"     18",
"    </a>",
"    ]. Every state public health laboratory in the United States now has the ability to respond to a biological terrorism emergency, either individually or through the regional or federal support system. &nbsp;",
"   </p>",
"   <p>",
"    Appropriate collection of clinical specimens is crucial to detection. Post-exposure specimens should be collected within the first 24 hours and prophylaxis should be offered (if available). Most clinical specimens include a nasal swab or sputum; culture and polymerase chain reaction (PCR) testing are usually performed. In some cases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    antibody testing (FA) is also possible, such as for Francisella tularensis. In general, for symptomatic patients, especially with pulmonary symptoms, lower respiratory tract sputums (induced if necessary) are ideal. Nasal swabs are an alternative.",
"   </p>",
"   <p>",
"    Serum is needed for toxin assays when botulism is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16715275\">",
"    <span class=\"h1\">",
"     DECONTAMINATION (OVERT EXPOSURE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of decontamination required in the event of a biological event depends on the degree of spread in an affected area, the number of individuals affected, and most critically, the organism of concern. Public health experts, emergency responders and possibly criminal experts will guide such a response. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1212302\">",
"    <span class=\"h2\">",
"     Personal decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;If personal decontamination is required, the CDC guidelines recommend that all clothing and personal effects be removed and placed in plastic bags. Persons should be instructed to shower using copious quantities of soap and water. Plastic bags with personal effects should be labeled clearly with the owner's name, contact telephone number, and inventory of the bag's contents. Personal items may be kept as evidence in a criminal trial or returned to the owner if the threat is unsubstantiated.",
"   </p>",
"   <p>",
"    Careful hand cleansing is important; one study evaluated different agents that might be used for hand washing after contact with anthrax [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/19\">",
"     19",
"    </a>",
"    ]. Regular soap and water were as effective in the removal of spores similar to anthrax as antimicrobial soap or 2 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    . However, an ethyl alcohol waterless rub was",
"    <strong>",
"     not",
"    </strong>",
"    active against these spores and is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11016?source=see_link&amp;anchor=H21#H21\">",
"     \"Prevention of anthrax\", section on 'Infection control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1212309\">",
"    <span class=\"h2\">",
"     Environmental decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental surfaces should be cleaned thoroughly after a suspected exposure once the crime scene investigation is complete. Surfaces may be decontaminated with a 0.5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/23/29042?source=see_link\">",
"     sodium hypochlorite solution",
"    </a>",
"    (ie, one part household bleach to 10 parts water) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/21\">",
"     21",
"    </a>",
"    ]. Personal effects may be decontaminated similarly.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/23/29042?source=see_link\">",
"     sodium hypochlorite",
"    </a>",
"    is a safe and effective decontaminating agent for environmental surfaces and equipment, it is not recommended for human skin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1212400\">",
"    <span class=\"h1\">",
"     WHO SHOULD RECEIVE PROPHYLAXIS?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determination of who should receive prophylaxis will depend on the suspected agent of concern and the associated route of transmission (for example, inhalational versus cutaneous). For example, what defines a &ldquo;close contact&rdquo; will be closely linked to whether the suspected agent is acquired through inhalation versus contact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1212415\">",
"    <span class=\"h1\">",
"     WHAT TYPE OF PROPHYLAXIS SHOULD BE GIVEN?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of prophylaxis will depend on the agent or toxin that is suspected.",
"   </p>",
"   <p>",
"    State and regional public health officials will guide clinicians as to the suspected pathogen and preferred prophylaxis to use depending on local supplies. The CDC Office of Health Preparedness and Response has developed the Strategic National Stockpile (SNS) for rapid response to such large-scale events with supplies to where they are needed most.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1212574\">",
"    <span class=\"h2\">",
"     Chemoprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemoprophylaxis is available for many infections, such as the etiologic agents of anthrax, plague, tularemia, brucellosis and Q fever.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    are used for the agents of anthrax, tularemia, and plague [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/22\">",
"     22",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    may have a role in chemoprophylaxis for glanders and melioidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/23\">",
"     23",
"    </a>",
"    ]. For brucellosis, combination therapy with doxycycline and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    for 21 days is preferred [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/24\">",
"     24",
"    </a>",
"    ]. The chemoprophylaxis of children or pregnant women requires a careful risk-benefit assessment, given the potential problems with antibiotics in special populations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link\">",
"     \"Fluoroquinolones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36662?source=see_link\">",
"     \"Tetracyclines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1212658\">",
"    <span class=\"h2\">",
"     Immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the principle of immunization to prevent disease has been shown to be effective in large-scale outbreaks (eg, H1N1 influenza vaccine), the value of mass vaccination after a biological event is unclear.",
"   </p>",
"   <p>",
"    In cases of suspected or documented bioterrorism, vaccines are available for the prevention of anthrax [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/25\">",
"     25",
"    </a>",
"    ], botulism, or cholera. Other vaccines are only available through special dispensation from the CDC (eg, vaccines effective against the causative agents of Q fever, the various viral encephalitides and viral hemorrhagic fevers). However, in contrast to antibiotics, vaccines are not usually stockpiled due to their typically short half-lives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1212665\">",
"    <span class=\"h2\">",
"     Antitoxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of antitoxins have been developed to counteract the effect of biologic agents. To date, these have been designed to protect against ricin, botulism and anthrax, although most have not progressed to commercial availability at this point [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/26\">",
"     26",
"    </a>",
"    ]. In December 2012, the US Food and Drug Administration approved",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32755?source=see_link\">",
"     raxibacumab",
"    </a>",
"    , a monoclonal antibody that neutralizes Bacillus anthracis toxin, for the prevention and treatment of inhalational anthrax [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/27\">",
"     27",
"    </a>",
"    ]. A supply of raxibacumab is held in the SNS in the event of an anthrax emergency. The use of raxibacumab is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11016?source=see_link&amp;anchor=H64397865#H64397865\">",
"     \"Prevention of anthrax\", section on 'Raxibacumab and other immunotherapeutics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16715289\">",
"    <span class=\"h1\">",
"     INFECTION CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC, in conjunction with the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Disease Society of America (IDSA) produced guidelines designed to assist in the care of hospitalized patients and outpatients regardless of their diagnosis or presumed infectious status [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Required precautions are disease specific; the types of precautions that are instituted will depend on the suspected or documented pathogen as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Airborne precautions (eg, smallpox, hemorrhagic fevers, tuberculosis, measles)",
"     </li>",
"     <li>",
"      Droplet precautions (eg, plague, influenza)",
"     </li>",
"     <li>",
"      Contact precautions (eg, salmonella)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Secondary person-to-person transmission is possible with a number of biologic agents, especially smallpox, pneumonic plague, and the agents of hemorrhagic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/29\">",
"     29",
"    </a>",
"    ]. Samples from toxin-exposed subjects can be dealt with routinely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16715296\">",
"    <span class=\"h1\">",
"     PSYCHOLOGICAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;One consequence of a terrorist attack is the residual psychological impact on the affected patients and the surrounding community. This will include overload of medical facilities by the &ldquo;worried well&rdquo; and grief responses by the survivors. Furthermore, past experience with the severe acute respiratory syndrome (SARS) suggested that some people who were ill delayed seeking care, because they perceived medical centers as being the source of the contagion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/30\">",
"     30",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Psychological morbidity for first-responders, medical personnel and the public can be significant in the event of a terrorist event, so clinicians should be mindful of depression, pathologic bereavement, acute stress disorder (ASD) and post-traumatic stress disorder (PTSD) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22247/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16715303\">",
"    <span class=\"h1\">",
"     EMERGENCY RESOURCES",
"    </span>",
"   </p>",
"   <p>",
"    CDC &ndash; Division of Emergency Preparedness and Response",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.bt.cdc.gov/emcontact/\">",
"     www.bt.cdc.gov/emcontact/",
"    </a>",
"   </p>",
"   <p>",
"    CDC Emergency Response Coordinating Group:",
"   </p>",
"   <p>",
"    770-488-7100 (health professionals or government officials only)",
"   </p>",
"   <p>",
"    Regional Poison Control Centers:",
"   </p>",
"   <p>",
"    1-800-222-1222",
"   </p>",
"   <p>",
"    CDC Coordinating Office for Terrorism Preparedness and Emergency Response:",
"   </p>",
"   <p>",
"    404-639-7405",
"   </p>",
"   <p>",
"    CDC Division of Bioterrorism Preparedness and Response:",
"   </p>",
"   <p>",
"    404-639-0385",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5182875\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Detection of biological agents can be difficult since biological events are frequently invisible and lead to slow accumulation of casualties, in contrast to chemical spills, which often lead to rapid casualties. (See",
"      <a class=\"local\" href=\"#H1212247\">",
"       'Detection of biologic events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An astute clinician may be the first to recognize either a large outbreak of one disease or an unusual pathogen, which may be the first sign of biological terrorism. (See",
"      <a class=\"local\" href=\"#H20472890\">",
"       'The role of the clinician'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effective surveillance systems for detection of biological outbreaks need to include real time data from emergency rooms, laboratories, pharmacies and even schools to identify patterns of illness. These early responses are important for timely distribution of prophylactic medications or vaccines. (See",
"      <a class=\"local\" href=\"#H16715254\">",
"       'Surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the event of a possible terrorist event, local emergency responses systems should be activated by dialing 911 in the United States, or equivalent emergency telephone numbers in other countries. (See",
"      <a class=\"local\" href=\"#H16715261\">",
"       'Public health response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The CDC has identified a number of pathogens that could be used in biological terrorism and have ranked them into various categories based on their overall potential to cause harm. The pathogens of greatest concern include anthrax and smallpox. (See",
"      <a class=\"local\" href=\"#H20472973\">",
"       'Organisms of concern'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Post-exposure specimens should be collected within the first 24 hours and prophylaxis should be offered (if available). Most clinical specimens include a nasal swab or sputum; culture and polymerase chain reaction (PCR) testing are usually performed. (See",
"      <a class=\"local\" href=\"#H16715268\">",
"       'Confirmation and diagnostic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In overt exposures, both personal and environmental decontamination may be required. (See",
"      <a class=\"local\" href=\"#H16715275\">",
"       'Decontamination (overt exposure)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      State and regional public health officials will guide clinicians as to the suspected pathogen and preferred prophylaxis to use depending on local supplies. (See",
"      <a class=\"local\" href=\"#H1212400\">",
"       'Who should receive prophylaxis?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The type of prophylaxis will depend on the agent or toxin that is suspected; possibilities include chemoprophylaxis, immunizations, or antitoxins.",
"     </li>",
"     <li>",
"      Airborne, droplet or contact precautions will be established depending on the agent of concern. (See",
"      <a class=\"local\" href=\"#H16715289\">",
"       'Infection control'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Eitzen E, Takafuji E. Textbook of Military Medicine, Chapter 18 Historical Overview of Biological Warfare &ndash; page 417; Office of the Surgeon General, Department of the Army, United States of America. file://www.bvsde.ops-oms.org/tutorial1/fulltex/armas/textos/chebio/chebio.pdf#page=424 (Accessed on January 11, 2013).",
"    </li>",
"    <li>",
"     Office of Technology Assessment, US Congress. Proliferation of Weapons of Mass Destruction. Washington, DC: US Government Printing Office; 1993:53-55. Publication OTA-ISC-559.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/3\">",
"      Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM Jr. Biological warfare. A historical perspective. JAMA 1997; 278:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/4\">",
"      Davis CJ. Nuclear blindness: An overview of the biological weapons programs of the former Soviet Union and Iraq. Emerg Infect Dis 1999; 5:509.",
"     </a>",
"    </li>",
"    <li>",
"     Kortepeter M, Christopher GW, Cieslak T, et al (Eds). Medical Management of Biological Casualties, 4th ed. USAMRIID, Ft Detrick, Frederick, Maryland, February 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/6\">",
"      Zilinskas RA. Iraq's biological weapons. The past as future? JAMA 1997; 278:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/7\">",
"      Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/8\">",
"      T&ouml;r&ouml;k TJ, Tauxe RV, Wise RP, et al. A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars. JAMA 1997; 278:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Update: Investigation of bioterrorism-related anthrax--Connecticut, 2001. MMWR Morb Mortal Wkly Rep 2001; 50:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Investigation of a ricin-containing envelope at a postal facility--South Carolina, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/11\">",
"      Dalton R. Biosafety lab passes disaster test. Nature 2008; 455:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/12\">",
"      Okumura T, Takasu N, Ishimatsu S, et al. Report on 640 victims of the Tokyo subway sarin attack. Ann Emerg Med 1996; 28:129.",
"     </a>",
"    </li>",
"    <li>",
"     Carus, WS. Bioterrorism and Biocrimes: The Illicit Use of Biological Agents Since 1900, Reprint of First Edition, Fredonia Books, Amsterdam 2002. p.63-65.",
"    </li>",
"    <li>",
"     CDC Division of Media Relations, CDC awards $2.7 million for two new Preparedness Research Centers; Jan 7, 2010 file://www.cdc.gov/media/pressrel/2010/r100107.htm (Accessed on January 11, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/15\">",
"      Biological and chemical terrorism: strategic plan for preparedness and response. Recommendations of the CDC Strategic Planning Workgroup. MMWR Recomm Rep 2000; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Bioterrorism Agents/Diseases, by Category file://emergency.cdc.gov/agent/agentlist-category.asp (Accessed on September 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/17\">",
"      Centers for Disease Control and Prevention (CDC). Neural tube defect surveillance and folic acid intervention--Texas-Mexico border, 1993-1998. MMWR Morb Mortal Wkly Rep 2000; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/18\">",
"      Butler D. European biosafety labs set to grow. Nature 2009; 462:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/19\">",
"      Weber DJ, Sickbert-Bennett E, Gergen MF, Rutala WA. Efficacy of selected hand hygiene agents used to remove Bacillus atrophaeus (a surrogate of Bacillus anthracis) from contaminated hands. JAMA 2003; 289:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/20\">",
"      Rutala WA, Weber DJ. Uses of inorganic hypochlorite (bleach) in health-care facilities. Clin Microbiol Rev 1997; 10:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/21\">",
"      Centers for Disease Control and Prevention (CDC). Bioterrorism alleging use of anthrax and interim guidelines for management--United States, 1998. MMWR Morb Mortal Wkly Rep 1999; 48:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/22\">",
"      Russell P, Eley SM, Bell DL, et al. Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice. J Antimicrob Chemother 1996; 37:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/23\">",
"      Russell P, Eley SM, Ellis J, et al. Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. J Antimicrob Chemother 2000; 45:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/24\">",
"      Robichaud S, Libman M, Behr M, Rubin E. Prevention of laboratory-acquired brucellosis. Clin Infect Dis 2004; 38:e119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/25\">",
"      Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996; 17:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/26\">",
"      Rainey GJ, Young JA. Antitoxins: novel strategies to target agents of bioterrorism. Nat Rev Microbiol 2004; 2:721.",
"     </a>",
"    </li>",
"    <li>",
"     FDA approves raxibacumab to treat inhalational anthrax, Dec. 14, 2012. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332341.htm (Accessed on January 11, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/28\">",
"      Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control 2007; 35:S65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/29\">",
"      Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2000; 283:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/30\">",
"      Rubin GJ, Dickmann P. How to reduce the impact of \"low-risk patients\" following a bioterrorist incident: lessons from SARS, anthrax, and pneumonic plague. Biosecur Bioterror 2010; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22247/abstract/31\">",
"      Smith CG, Veenhuis PE, MacCormack JN. Bioterrorism. A new threat with psychological and social sequelae. N C Med J 2000; 61:150.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2735 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.28.111.102-322217C268-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_46_22247=[""].join("\n");
var outline_f21_46_22247=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5182875\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16715219\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16715226\">",
"      HISTORY OF BIOLOGICAL WEAPONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16715233\">",
"      EVIDENCE OF PRIOR BIOTERRORISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1211773\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1211780\">",
"      Worldwide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20472916\">",
"      THE ROLE OF REGULATORY AGENCIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1212247\">",
"      DETECTION OF BIOLOGIC EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20472890\">",
"      THE ROLE OF THE CLINICIAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16715254\">",
"      SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16715261\">",
"      PUBLIC HEALTH RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20472973\">",
"      ORGANISMS OF CONCERN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5382341\">",
"      TOXINS OF CONCERN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16715268\">",
"      CONFIRMATION AND DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16715275\">",
"      DECONTAMINATION (OVERT EXPOSURE)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1212302\">",
"      Personal decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1212309\">",
"      Environmental decontamination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1212400\">",
"      WHO SHOULD RECEIVE PROPHYLAXIS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1212415\">",
"      WHAT TYPE OF PROPHYLAXIS SHOULD BE GIVEN?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1212574\">",
"      Chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1212658\">",
"      Immunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1212665\">",
"      Antitoxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16715289\">",
"      INFECTION CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16715296\">",
"      PSYCHOLOGICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16715303\">",
"      EMERGENCY RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5182875\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2735\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2735|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/15/37116\" title=\"table 1\">",
"      Bioterrorism agents by category",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8521?source=related_link\">",
"      Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7224?source=related_link\">",
"      Clinical manifestations and diagnosis of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=related_link\">",
"      Microbiology and epidemiology of salmonellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39079?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11016?source=related_link\">",
"      Prevention of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36662?source=related_link\">",
"      Tetracyclines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35797?source=related_link\">",
"      The epidemiology, pathogenesis, and clinical manifestations of smallpox",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_46_22248="What's new in hematology";
var content_f21_46_22248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   What's new in hematology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/46/22248/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/46/22248/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/46/22248/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/46/22248/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/46/22248/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Chimeric antigen receptor-modified T cells",
"    </span>",
"   </p>",
"   <p>",
"    The majority of adults diagnosed with acute B cell lymphoblastic leukemia (B-ALL) will have primary resistant disease or relapse following an initial response to therapy. A novel investigational treatment approach uses T cells from the patient that have been modified to target cells that express CD19. In one report, all five patients with relapsed B-ALL who received these chimeric antigen receptor modified T (CAR-T) cells&nbsp;attained a molecular remission, allowing for subsequent hematopoietic cell transplantation&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/1\">",
"     1",
"    </a>",
"    ]. Toxicity included significant cytokine elevations. A second report described similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/2\">",
"     2",
"    </a>",
"    ]. Further follow-up of these patients and larger trials are needed to determine the efficacy and safety of this approach.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21753?source=see_link&amp;anchor=H23720941#H23720941\">",
"     \"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults\", section on 'Clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Arsenic trioxide plus ATRA for acute promyelocytic leukemia",
"    </span>",
"   </p>",
"   <p>",
"    The combination of arsenic trioxide (ATO) plus all-trans retinoic acid (ATRA) is capable of producing complete molecular remissions in previously untreated acute promyelocytic leukemia (APL). Until recently, ATO plus ATRA had not been compared directly with standard induction therapy, ATRA plus chemotherapy. Preliminary results are available from the Intergroup APL0406 randomized phase III trial comparing ATRA plus ATO with ATRA plus idarubicin (AIDA) in over 150 adults with newly diagnosed low- or intermediate-risk APL [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/3\">",
"     3",
"    </a>",
"    ]. When compared with AIDA, ATRA plus ATO was associated with fewer deaths during induction therapy and similar rates of complete remission and rates of relapse at two years, resulting in a superior estimated event-free and overall survival at two years. These results suggest that the combination of ATRA plus ATO without chemotherapy may be a good alternative for chemotherapy-based regimens in low-risk and intermediate-risk APL. While we await the final publication of this study, we reserve ATO plus ATRA for patients, such as older adults, who are not able to tolerate anthracycline-based therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'Arsenic trioxide plus ATRA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Decitabine for acute myeloid leukemia in older adults",
"    </span>",
"   </p>",
"   <p>",
"    Many older adults with acute myeloid leukemia (AML) are not candidates for standard remission induction chemotherapy due to anticipated toxicity. DNA hypomethylating agents (azacitidine and decitabine) are commonly used for the treatment of myelodysplastic syndromes (MDS) and have lower rates of toxicity. In a large multicenter trial, adults &ge;65 years with newly diagnosed AML were randomly assigned to decitabine or to a therapy of their choice (supportive care alone or low-dose cytarabine) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/4\">",
"     4",
"    </a>",
"    ]. Decitabine was associated with a higher complete remission rate and a trend towards improved survival. This and similar trials of azacitidine suggest that DNA hypomethylating agents can provide benefit without excessive toxicity for older adults with AML. In July 2012, the European Medicines Agency (EMA) approved decitabine for the treatment of AML in older adults. Azacitidine had previously been approved for the treatment of AML that has developed from MDS. Although neither agent has been approved in the United States for the treatment of AML, both can now be considered acceptable options in this patient population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link&amp;anchor=H1358586#H1358586\">",
"     \"Treatment of acute myeloid leukemia in older adults\", section on 'DNA hypomethylating agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Liposomal vincristine for acute lymphoblastic leukemia",
"    </span>",
"   </p>",
"   <p>",
"    Liposomal vincristine is a new formulation of vincristine sulfate that has a longer half-life than conventional vincristine. A phase II, single arm trial of single agent liposomal vincristine in 65 adults with relapsed Philadelphia chromosome negative acute lymphoblastic leukemia (Ph- ALL) reported a complete remission (CR) or CR with incomplete blood count recovery in approximately 20 percent of patients with a median remission duration of 23 weeks&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/5\">",
"     5",
"    </a>",
"    ].&nbsp;Severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicities included infections, neuropathy, and cytopenias. Liposomal vincristine received accelerated approval from the US Food and Drug Administration in August 2012 for the treatment of adults with Ph- ALL in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. We await results of studies comparing this agent with conventional vincristine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21753?source=see_link&amp;anchor=H2914156#H2914156\">",
"     \"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults\", section on 'Liposomal vincristine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ANEMIA AND OTHER RED CELL DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Erythropoiesis stimulating agents in heart failure",
"    </span>",
"   </p>",
"   <p>",
"    The available evidence does not support the use of erythropoiesis stimulating agents to treat anemia in patients with heart failure. The best evidence on the lack of efficacy and risk of complications of such treatment in this population comes from the RED-HF trial which randomly assigned 2278 patients with systolic heart failure to treatment with either darbepoetin alfa or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/6\">",
"     6",
"    </a>",
"    ]. Darbepoetin alfa and placebo-treated groups had similar rates of the primary outcome of death from any cause or hospitalization for worsening heart failure at median 28 months follow-up. Rates of thromboembolic adverse events were more frequent in the darbepoetin alfa-treated group (13.5 versus 10.0 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=see_link&amp;anchor=H15#H15\">",
"     \"Impact of anemia in patients with heart failure\", section on 'Erythropoiesis stimulating agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Peginesatide, cardiovascular events, and drug withdrawal",
"    </span>",
"   </p>",
"   <p>",
"    Peginesatide is a synthetic peptide that stimulates&nbsp;hematopoiesis but does not cross react with erythropoietin antibodies. Pooled data from two randomized open-label studies in hemodialysis patients&nbsp;(EMERALD 1 and EMERALD 2) showed that peginesatide was&nbsp;as effective as&nbsp;erythropoietin in maintaining the hemoglobin concentration among hemodialysis patients and&nbsp;there was no difference in a cardiovascular safety endpoint [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/7\">",
"     7",
"    </a>",
"    ].&nbsp;However, two randomized studies (PEARL-1 and PEARL-2) that compared peginesatide to darbepoetin among non-dialysis chronic kidney disease (CKD) patients showed that peginesatide increased cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/8\">",
"     8",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Subsequent to approval of peginesatide by the U.S. Food and Drug Administration and publication of these studies, peginesatide was withdrawn from the market and distributed lots recalled&nbsp;due to serious hypersensitivity reactions reported in patients following the first dose of intravenous administration with death occurring in 0.02 percent of patients&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/9\">",
"     9",
"    </a>",
"    ].(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link&amp;anchor=H1130568215#H1130568215\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\", section on 'Peginesatide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CHRONIC LEUKEMIAS AND THE MYELOPROLIFERATIVE NEOPLASMS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chlorambucil for older adults with chronic lymphocytic leukemia",
"    </span>",
"   </p>",
"   <p>",
"    There is no agreed upon standard treatment regimen for patients with&nbsp;previously untreated, symptomatic chronic lymphocytic leukemia (CLL). The choice of therapy is particularly difficult&nbsp;for patients &gt;70 years who have varying levels of co-morbidities and performance status. While many clinicians prefer fludarabine-containing&nbsp;regimens for younger adults, older adults have a higher rate of toxicities and opportunistic infections with these regimens. An analysis of&nbsp;over 650&nbsp;CLL patients enrolled&nbsp;in several&nbsp;trials of initial therapy demonstrated a survival benefit for fludarabine compared with chlorambucil among patients younger than 70 years, but not in those over 70 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/10\">",
"     10",
"    </a>",
"    ]. Based upon these and other data, we&nbsp;suggest initial treatment with chlorambucil rather than fludarabine or other agents for most older adults with symptomatic CLL; selected older patients in general good health other than CLL may reasonably be initially treated with other agents.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6362?source=see_link&amp;anchor=H5624031#H5624031\">",
"     \"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia\", section on 'Older adults'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     The optimal hematocrit in polycythemia vera",
"    </span>",
"   </p>",
"   <p>",
"    The optimal hematocrit in polycythemia vera (PV) was addressed in a prospective randomized trial in 365 adults with PV receiving treatment with phlebotomy, hydroxyurea, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/11\">",
"     11",
"    </a>",
"    ]. Subjects were randomly assigned to receive either more intensive treatment (target hematocrit &lt;45 percent) or less intensive treatment (target hematocrit 45 to 50 percent). After a median follow-up of 31 months, death from cardiovascular causes or major thrombotic events, the primary efficacy endpoint, occurred in 2.7 and 9.8 percent of those in the lower and higher hematocrit groups, respectively. The rates of adverse events (ie, progression to myelofibrosis or myelodysplasia, leukemic transformation, bleeding) were not significantly different between the two treatment arms. As a result, we recommend that the hematocrit in PV be maintained at less than 45 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28554?source=see_link&amp;anchor=H8323402#H8323402\">",
"     \"Prognosis and treatment of polycythemia vera\", section on 'The optimal hematocrit in PV'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ponatinib for CML",
"    </span>",
"   </p>",
"   <p>",
"    The majority of patients with chronic phase chronic myeloid leukemia (CML) are treated initially with a first or second generation BCR-ABL tyrosine kinase inhibitor (TKI). Second generation TKIs can also be used for most patients with intolerance or resistance to initial therapy. However, patients with resistant disease that demonstrates the T315I BCR-ABL mutation only rarely respond to available TKIs. Ponatinib is a new BCR-ABL TKI that has activity in patients with relapsed or refractory CML, including those with the T315I mutation. A phase I dose escalation study of ponatinib reported high response rates in 43 patients with heavily pretreated chronic phase CML [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/12\">",
"     12",
"    </a>",
"    ]. Importantly, of the 12 patients with T315I mutation, all attained a complete hematologic response. Major cytogenetic response, complete cytogenetic response, and major molecular response were seen in 11, 9, and 8 patients, respectively. High response rates in patients with T315I mutation were also demonstrated in a phase II trial of ponatinib, available in abstract form only [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Ponatinib was approved in December 2012 by the US Food and Drug Administration for the treatment of adults with CML resistant to or intolerant of prior TKI therapy, accompanied by a boxed warning alerting patients and clinicians to the potential of arterial thrombosis and liver toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/15\">",
"     15",
"    </a>",
"    ]. However, given the short follow-up of patients treated with ponatinib, and the fact that allogeneic hematopoietic cell transplantation (HCT) offers potential cure in patients with the T315I mutation, we suggest that eligible patients with CML resistant to an initial TKI who harbor the T315I mutation be evaluated for HCT. Ponatinib represents an alternative for such patients and is our preferred treatment for HCT ineligible patients with the T315I mutation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link&amp;anchor=H12149527#H12149527\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\", section on 'Ponatinib'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=see_link&amp;anchor=H12150663#H12150663\">",
"     \"Treatment of chronic myeloid leukemia in blast crisis\", section on 'Ponatinib'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=see_link&amp;anchor=H12150432#H12150432\">",
"     \"Treatment of chronic myeloid leukemia in accelerated phase\", section on 'Ponatinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Omacetaxine mepesuccinate for CML",
"    </span>",
"   </p>",
"   <p>",
"    Omacetaxine mepesuccinate (previously known as homoharringtonine) is a protein synthesis inhibitor that was approved in October 2012 by the US Food and Drug Administration for the treatment of adults with chronic myeloid leukemia (CML) in chronic or accelerated phase resistant to or intolerant of two or more tyrosine kinase inhibitors (TKIs) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Uncontrolled prospective trials have demonstrated modest activity including responses in patients with CML that contained the T315I BCR-ABL mutation, a mutation known to be resistant to all available TKIs. Common toxicities included anemia, neutropenia, thrombocytopenia, infection, and gastrointestinal distress. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link&amp;anchor=H24874435#H24874435\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\", section on 'Omacetaxine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=see_link&amp;anchor=H24874649#H24874649\">",
"     \"Treatment of chronic myeloid leukemia in accelerated phase\", section on 'Omacetaxine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nodal response in CLL",
"    </span>",
"   </p>",
"   <p>",
"    For patients with chronic lymphocytic leukemia (CLL), standard criteria for determining response to therapy rely upon surrogate markers of tumor burden (eg, blood lymphocyte count, lymph node size, spleen size) that have predicted clinical benefit in patients treated with traditional chemotherapy. However, these response criteria may not always accurately predict clinical benefit in patients treated with investigational agents. In particular, patients treated with drugs thought to mobilize tumor from tissues into the peripheral blood (eg, B cell receptor and adhesion-related kinase inhibitors) may rapidly develop a lymphocytosis that can either persist or decline with time, and is accompanied by shrinkage of the involved lymph nodes. In this setting, the lymphocytosis is not thought to represent progression, but to be a positive development. A Lymphoma Research Foundation-sponsored workshop has suggested modification of the response criteria for patients on clinical trials receiving such drugs, and the term 'nodal response' to describe the phenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/18\">",
"     18",
"    </a>",
"    ]. The term nodal response is currently reserved for patients on clinical trials. Patients treated outside of a clinical trial who develop lymphocytosis should be considered to have progressive disease, regardless of changes in lymph node size. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17671?source=see_link&amp;anchor=H16073330#H16073330\">",
"     \"Evaluating response to treatment of chronic lymphocytic leukemia\", section on 'Nodal response'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     HEMATOPOIETIC CELL TRANSPLANTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chlorhexidine bathing for intensive care and hematopoietic cell transplant patients",
"    </span>",
"   </p>",
"   <p>",
"    Use of antiseptic agents for patient bathing has been demonstrated to reduce the rate of hospital-acquired bloodstream infections and the risk of colonization with drug-resistant organisms. The greatest efficacy has been demonstrated with chlorhexidine gluconate, an antiseptic agent with broad-spectrum activity. Among more than 7000 patients in intensive care and&nbsp;hematopoietic cell&nbsp;transplant units randomly assigned&nbsp;to bathing with either 2 percent chlorhexidine-impregnated washcloths or nonantimicrobial washcloths for a six-month period (followed by crossover for the alternate product for the subsequent six months), chlorhexidine bathing was associated with reduction in the rate of hospital-acquired bloodstream infections by 28 percent and reduction in the rate of colonization with drug-resistant organisms by 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link&amp;anchor=H3992580#H3992580\">",
"     \"General principles of infection control\", section on 'Patient bathing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Expansion of umbilical cord blood in culture",
"    </span>",
"   </p>",
"   <p>",
"    The use of umbilical cord blood (UCB) for hematopoietic cell transplantation is limited by the numbers of hematopoietic progenitors (ie, cell dose) in the graft. Since low cell dose results in delayed engraftment and a high rate of graft failure, techniques to improve cell dose are needed. One such technique is ex vivo expansion of hematopoietic progenitors in culture supported by mesenchymal stromal cells. In a prospective study, 24 adults with hematologic cancers were treated with myeloablative conditioning followed by the infusion of one unmanipulated UCB unit and one UCB unit that had undergone ex vivo expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/20\">",
"     20",
"    </a>",
"    ]. When compared with matched historical controls that received two unmanipulated UCB grafts, patients who received an expanded UCB graft had shorter median times to neutrophil engraftment and platelet engraftment without increased toxicity. While not available for widespread use, this technique may further expand the availability of UCB transplantation in the future. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15865?source=see_link&amp;anchor=H4260926#H4260926\">",
"     \"Selection of an umbilical cord blood graft for hematopoietic cell transplantation\", section on 'Improving cell dose'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Peripheral blood progenitor cell versus bone marrow transplant",
"    </span>",
"   </p>",
"   <p>",
"    Peripheral blood progenitor cells (PBPCs) have replaced bone marrow as the source of hematopoietic stem cells for many patients undergoing allogeneic hematopoietic cell transplantation (HCT). A phase III randomized trial in adults compared PBPCs with bone marrow, both obtained from HLA-matched unrelated donors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/21\">",
"     21",
"    </a>",
"    ]. When compared with bone marrow, PBPCs resulted in similar survival rates, significantly quicker engraftment, fewer cases of graft failure, similar rates of acute graft versus host disease (GVHD), but increased rates of chronic extensive GVHD. These results suggest that both PBPCs and bone marrow are acceptable stem cell sources. PBPC may be preferred for those at high risk of graft failure or infections in the early post-transplantation period where more rapid hematopoietic recovery could be a particular advantage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H18#H18\">",
"     \"Sources of hematopoietic stem cells\", section on 'Allogeneic transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     HEMOSTASIS AND THROMBOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Risk of inhibitor development in patients with hemophilia A",
"    </span>",
"   </p>",
"   <p>",
"    Up to&nbsp;one-third of patients with severe hemophilia A produce antibodies (ie, inhibitors) to infused factor VIII;&nbsp;the incidence of inhibitor development&nbsp;with different products is not well studied. To address product-related factors, over 500 previously untreated children with severe hemophilia A were followed prospectively after receiving the factor VIII product chosen by their physician [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/22\">",
"     22",
"    </a>",
"    ]. The risk of inhibitor formation was similar with recombinant and plasma-derived products and was not affected by the amount of von Willebrand factor in the product&nbsp;or by switching products. Second-generation full-length recombinant products had a slightly higher risk of inhibitor development compared with third-generation recombinant products. Other factors such as cost, safety, and purity continue to be important in the choice of factor VIII product. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=see_link&amp;anchor=H15593804#H15593804\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\", section on 'Replacement product'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Enteric coating affects aspirin absorption",
"    </span>",
"   </p>",
"   <p>",
"    Enteric coated aspirin is sometimes administered instead of non-enteric coated (ie, dispersible or immediate release) aspirin to reduce gastrointestinal toxicity, but data regarding the impact of enteric coating on absorption are limited. The antithrombotic effect of these formulations was tested by measuring platelet function in 400 volunteers administered a single oral dose of 325 mg enteric coated or non-enteric coated aspirin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/23\">",
"     23",
"    </a>",
"    ]. Apparent nonresponse was common following enteric coated aspirin, but not non-enteric coated aspirin. All of the individuals with apparent nonresponse after initial dosing showed an adequate response to aspirin upon one of the following: change to non-enteric coated aspirin; administration of serial doses of enteric coated aspirin; or addition of aspirin to their platelets in vitro. The study thus failed to identify a single case of true aspirin resistance. This study supports our preference for non-enteric coated aspirin in the setting of acute thrombotic events to ensure a rapid clinical antithrombotic effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19401?source=see_link&amp;anchor=H437013703#H437013703\">",
"     \"Nonresponse and resistance to aspirin\", section on 'Use of enteric coated aspirin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H21#H21\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Aspirin formulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Apixaban for secondary prevention of venous thromboembolism",
"    </span>",
"   </p>",
"   <p>",
"    The randomized, double-blind AMPLIFY-EXT study compared the efficacy and safety of apixaban with placebo in over 2000 subjects with venous thromboembolism (VTE) who had completed 6 to 12 months of anticoagulation and for whom there was uncertainty regarding the further continuation of anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/24\">",
"     24",
"    </a>",
"    ]. Symptomatic recurrent VTE or death from VTE occurred in 8.8 and 1.7 percent of those receiving placebo or apixaban, respectively, for an overall 80 percent reduction in the risk of VTE recurrence with apixaban. Major bleeding was not increased in the group receiving apixaban. A randomized trial comparing this agent with standard-dose warfarin will help to determine the future role of apixaban for the continued treatment of VTE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H7480111#H7480111\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Apixaban'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H30#H30\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Issues to consider'",
"    </a>",
"    .)&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Aspirin for secondary prevention of venous thromboembolism",
"    </span>",
"   </p>",
"   <p>",
"    Two randomized trials, WARFASA and ASPIRE, examined the use of low-dose aspirin (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for the prevention of recurrent venous thromboembolism (VTE)&nbsp;following&nbsp;6 to 18 months of anticoagulation for a&nbsp;first unprovoked episode of VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. WARFASA showed a significant reduction in the rate of VTE recurrence, in contrast to&nbsp;ASPIRE, which failed&nbsp;to meet&nbsp;its primary end point of significant&nbsp;risk reduction of recurrent&nbsp;VTE.&nbsp;A prospectively planned combined analysis of both trials indicated that aspirin, compared with placebo, significantly reduced both the rate of VTE recurrence and major vascular events (a composite&nbsp;secondary endpoint of&nbsp;recurrent VTE, myocardial infarction, stroke, and cardiovascular death) by 32 and 34 percent, respectively, with no excess bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/26\">",
"     26",
"    </a>",
"    ]. After completing anticoagulant therapy following a first-time unprovoked VTE, switching to low-dose aspirin,&nbsp;is an option that may reduce the risk&nbsp; of VTE recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/27\">",
"     27",
"    </a>",
"    ].&nbsp;Direct comparison of aspirin and warafarin for the prevention of VTE was not performed&nbsp;in either&nbsp;trial and warrants further study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H11015892#H11015892\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Use of aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     LYMPHOMA: HODGKIN AND NON-HODGKIN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Bendamustine plus rituximab in mantle cell lymphoma",
"    </span>",
"   </p>",
"   <p>",
"    Chemotherapy and immunotherapy with rituximab are key components to the initial treatment of&nbsp;patients with mantle cell lymphoma (MCL), although the optimal chemotherapy regimen is not clear. The relatively new combination of bendamustine plus rituximab (BR) was compared with standard R-CHOP in a randomized, phase III trial of over 500 patients with advanced stage indolent non-Hodgkin lymphoma, which included&nbsp;94 patients with&nbsp;MCL [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/28\">",
"     28",
"    </a>",
"    ]. BR resulted in superior median progression-free survival&nbsp;and equivalent&nbsp;overall survival, with less toxicity. For most patients with MCL we now&nbsp;consider the off-label use of BR to be an acceptable treatment option. The long-term toxicity profile and impact on future treatments, including hematopoietic stem cell collection, are unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17402?source=see_link&amp;anchor=H7#H7\">",
"     \"Initial treatment of mantle cell lymphoma\", section on 'Conventional chemoimmunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Bendamustine plus rituximab for newly diagnosed follicular lymphoma",
"    </span>",
"   </p>",
"   <p>",
"    Rituximab is central to the treatment of patients with advanced stage follicular lymphoma (FL). It can&nbsp;be administered either alone or in combination with chemotherapy, although the&nbsp;optimal chemotherapy regimen is not clear. The relatively new combination of bendamustine plus rituximab (BR) was compared with standard R-CHOP in a randomized, phase III trial of&nbsp;over 500&nbsp;patients with advanced stage indolent non-Hodgkin lymphoma, including FL [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/28\">",
"     28",
"    </a>",
"    ]. BR resulted in superior median progression-free survival and&nbsp;equivalent overall survival,&nbsp;with less toxicity. The long-term toxicity profile and impact on future treatments, including hematopoietic stem cell collection, are unknown.&nbsp;For&nbsp;most patients with advanced stage&nbsp;FL, we now prefer BR over R-CHOP.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link&amp;anchor=H19675543#H19675543\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\", section on 'Chemoimmunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Anti-CD20 radioimmunoconjugates as initial therapy in follicular lymphoma",
"    </span>",
"   </p>",
"   <p>",
"    Anti-CD20 radioimmunoconjugates (eg, ibritumomab tiuxetan, tositumomab) have demonstrated efficacy in relapsed or refractory follicular lymphoma (FL). Nonrandomized trials have also evaluated the off-label use of radioimmunoconjugates as single-agent therapy for the management of previously untreated FL. In a phase II trial of 59 patients with previously untreated stage II to IV FL requiring therapy, ibritumomab tiuxetan resulted in an overall response rate of 87 percent at six months with 56 percent of patients achieving a complete remission or an unconfirmed complete remission [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/29\">",
"     29",
"    </a>",
"    ]. After a median follow-up of 31 months, the median progression-free survival was 26 months and the median overall survival had not been reached. As expected, approximately half developed severe cytopenias. Non-hematologic toxicities were mostly mild to moderate and included infections and gastrointestinal toxicities. While these initial reports suggest good response rates and tolerability, long-term follow-up of such an approach is limited. Until more definitive data are available, we do",
"    <strong>",
"     not",
"    </strong>",
"    use radioimmunoconjugates as part of first-line therapy for most patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link&amp;anchor=H19675564#H19675564\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\", section on 'Radioimmunoconjugates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Staging bone marrow biopsy in Hodgkin lymphoma",
"    </span>",
"   </p>",
"   <p>",
"    The value of bone marrow biopsy in the staging of Hodgkin lymphoma (HL) has steadily decreased with the improvement of noninvasive imaging studies and the evolution of treatment paradigms to include the use of systemic chemotherapy for all patients. In a retrospective analysis of 454 patients with newly diagnosed HL who had undergone pretreatment",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    and bone marrow biopsy, no patients with stage I or II HL by",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    had bone marrow involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/30\">",
"     30",
"    </a>",
"    ]. While five patients were converted from stage III to stage IV disease based upon the bone marrow biopsy results alone, none resulted in a change in treatment strategy. Based upon this and other studies, we no longer advocate the use of bone marrow biopsy in the staging of any patients with HL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial evaluation and diagnosis of Hodgkin lymphoma in adults\", section on 'Bone marrow biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Hodgkin lymphoma in HIV infected patients",
"    </span>",
"   </p>",
"   <p>",
"    Hodgkin lymphoma (HL) is among the most common non-AIDS-defining malignancies in HIV positive patients. In this setting, HL often presents with more aggressive disease than in non-HIV infected persons. Two large studies in HIV positive patients found that progression-free survival and overall survival were not adversely affected by HIV status when patients were treated with antiretroviral therapy combined with standard chemotherapy regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link&amp;anchor=H1560506291#H1560506291\">",
"     \"HIV infection and malignancy: Management considerations\", section on 'Hodgkin lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     \"Double-hit\" lymphoma",
"    </span>",
"   </p>",
"   <p>",
"    The term &ldquo;double-hit&rdquo; lymphoma is used colloquially to refer to cases of lymphoma that contain translocations of both the c-MYC gene at 8q24 and a second site, often the BCL-2 gene at 18q21. &ldquo;Double-hit&rdquo;",
"    <span class=\"nowrap\">",
"     c-MYC/BCL-2",
"    </span>",
"    lymphomas identified by genetic testing have a very poor prognosis. In contrast, the prognostic impact of",
"    <span class=\"nowrap\">",
"     c-MYC/BCL-2",
"    </span>",
"    overexpression identified by immunohistochemistry is not known. In two independent studies, coexpression of c-MYC and BCL-2 was seen in 21 to 29 percent of cases of diffuse large B cell lymphoma and predicted a lower complete response rate and shorter progression-free and overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Further studies are needed to clarify the prognosis of lymphomas that overexpress BCL-2 and c-MYC based on immunohistochemistry. For now, genetic testing for c-MYC translocations should be considered in cases with c-MYC overexpression identified by immunohistochemistry. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29127?source=see_link&amp;anchor=H14049240#H14049240\">",
"     \"Prognosis of diffuse large B cell lymphoma\", section on '\"Double-hit\" lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     EBV-DNA levels in extranodal NK/T cell lymphoma, nasal type",
"    </span>",
"   </p>",
"   <p>",
"    Extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type is an uncommon lymphoma of",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell origin, which appears to be at least partially due to infection of the tumor cells with Epstein-Barr virus (EBV). Levels of EBV in the plasma correlate with patient outcomes and may serve as an indirect measure of tumor burden before and after treatment. In a small prospective observational study, when compared with those with lower levels, patients with high pretreatment plasma EBV-DNA levels had lower estimated progression-free survival (PFS) and overall survival (OS) at three years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/35\">",
"     35",
"    </a>",
"    ]. Post-treatment plasma EBV-DNA levels also provided a measure of disease response to therapy. Patients with undetectable EBV-DNA following therapy had significantly higher estimated rates of PFS and OS. Based upon this and other studies, we incorporate plasma EBV-DNA into our evaluation of disease status, both before and after therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     MULTIPLE MYELOMA AND OTHER PLASMA CELL DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Fludarabine versus chlorambucil for Waldenstr&ouml;m macroglobulinemia",
"    </span>",
"   </p>",
"   <p>",
"    Most experts agree that the initial therapy of patients with symptomatic Waldenstr&ouml;m macroglobulinemia (WM) should incorporate rituximab.&nbsp;Chemotherapy alone may be an alternative initial therapy in patients with a high tumor burden who are unable to tolerate rituximab therapy.&nbsp;Until now, there had been no randomized trials to guide the choice of chemotherapy agents.&nbsp;A&nbsp;large randomized phase III trial of patients with newly diagnosed non-Hodgkin lymphoma, including 339 patients with WM,&nbsp;compared chlorambucil with fludarabine,&nbsp;each as single agents&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/36\">",
"     36",
"    </a>",
"    ]. Fludarabine was associated with a higher rate of severe neutropenia. After a median follow-up of 36 months, when compared with chlorambucil, fludarabine resulted in&nbsp;superior progression free survival. A subset analysis of patients with WM demonstrated a survival advantage with fludarabine.&nbsp;",
"    <br/>",
"    <br/>",
"    While&nbsp;fludarabine&nbsp;appears to be superior to chlorambucil for most populations, chlorambucil may still be considered for older adults (eg, &ge;70 years) with a high tumor burden who are unable to receive rituximab or who have already failed rituximab-based therapy. Such patients would be expected to have greater toxicity with fludarabine therapy.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37626?source=see_link&amp;anchor=H12860436#H12860436\">",
"     \"Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Choice of agent'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Pomalidomide for relapsed multiple myeloma",
"    </span>",
"   </p>",
"   <p>",
"    Pomalidomide is a thalidomide analog that was approved by the US Food and Drug Administration in February 2013 for patients with&nbsp;multiple myeloma&nbsp;who have received at least two prior therapies, including bortezomib and lenalidomide, and have demonstrated disease progression on or within 60 days of the completion of the last therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/37\">",
"     37",
"    </a>",
"    ].&nbsp;In this&nbsp;patient population, approximately one-quarter of cases demonstrate at least a&nbsp;partial response to treatment with pomalidomide plus low-dose dexamethasone, with a median duration of response of seven months.&nbsp;Toxicities include cytopenias and their complications (eg, infection), increased risk for venous thromboembolism, and teratogenicity. Pomalidomide is only available through the Pomalyst REMS program.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link&amp;anchor=H349206892#H349206892\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Pomalidomide'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/33/33303?source=see_link\">",
"     \"Pomalidomide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Monoclonal gammopathy of renal significance",
"    </span>",
"   </p>",
"   <p>",
"    The term &ldquo;monoclonal gammopathy of renal significance&rdquo; (MGRS) has been proposed by the International Kidney and Monoclonal Gammopathy Research Group to describe cases that would otherwise meet the criteria for monoclonal gammopathy of undetermined significance (MGUS), but demonstrate monoclonal immunoglobulin deposits in the kidney by immunofluorescence [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/38\">",
"     38",
"    </a>",
"    ]. The presence of MGUS is",
"    <strong>",
"     not",
"    </strong>",
"    in itself an indication for renal biopsy and the introduction of this terminology does not change the indications for renal biopsy. However, this distinction between MGUS and MGRS is important because the monoclonal protein appears to be the direct cause of kidney disease in such cases, and treatment that targets the responsible clone is associated with restoration and preservation of kidney function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13594?source=see_link&amp;anchor=H56342434#H56342434\">",
"     \"Evaluation and treatment of membranoproliferative glomerulonephritis\", section on 'Treatment of the underlying cause'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link&amp;anchor=H2549497#H2549497\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\", section on 'Monoclonal gammopathy of renal significance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     TRANSFUSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Blood transfusion thresholds for acute upper GI bleeding",
"    </span>",
"   </p>",
"   <p>",
"    The decision to initiate blood transfusions in patients with acute upper gastrointestinal bleeding is based on the rapidity of bleeding and the patients' comorbid conditions. A randomized trial of patients with and without cardiovascular disease suggests that in patients who are not at increased risk for complications from anemia, outcomes are improved if a lower hemoglobin threshold (&lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    rather than &lt;9",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    is used for initiating blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients transfused when the hemoglobin was &lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    had lower mortality rates, were less likely to have further bleeding, and were less likely to suffer complications.",
"    <br/>",
"    <br/>",
"    We recommend giving blood transfusions to maintain the hemoglobin at &ge;7",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    rather than &ge;9",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    for the majority of patients with acute upper gastrointestinal bleeding who do not have significant comorbid illnesses. However, patients with active bleeding and hypovolemia may require blood transfusion despite an apparently normal hemoglobin. Additionally, we suggest transfusing to maintain the hemoglobin at &ge;9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for patients at increased risk of adverse events in the setting of significant anemia, such as those with unstable coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H5079586#H5079586\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Blood transfusions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\", section on 'Blood transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Prophylactic versus therapeutic platelet transfusion",
"    </span>",
"   </p>",
"   <p>",
"    To prevent spontaneous bleeding in patients with severe thrombocytopenia from bone marrow suppression, standard practice is to transfuse platelets prophylactically at a specified threshold platelet count (usually",
"    <span class=\"nowrap\">",
"     10,000/microL).",
"    </span>",
"    Two recently completed randomized trials in patients with severe thrombocytopenia due to acute myeloid leukemia, chemotherapy, or autologous hematopoietic cell transplantation have compared this approach with therapeutic transfusion only for active bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Compared with patients who were transfused for a threshold platelet count of",
"    <span class=\"nowrap\">",
"     &le;10,000/microL,",
"    </span>",
"    patients who were only transfused for active bleeding had more frequent episodes of bleeding and more severe bleeding (including fatal intracranial hemorrhage). These results support the current practice of prophylactic platelet transfusion at a threshold platelet count of",
"    <span class=\"nowrap\">",
"     10,000/microL",
"    </span>",
"    in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H323107#H323107\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Therapeutic versus prophylactic transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     OTHER HEMATOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Enteric coating affects aspirin absorption",
"    </span>",
"   </p>",
"   <p>",
"    Enteric coated aspirin is sometimes administered instead of non-enteric coated (ie, dispersible or immediate release) aspirin to reduce gastrointestinal toxicity, but data regarding the impact of enteric coating on absorption are limited. The antithrombotic effect of these formulations was tested by measuring platelet function in 400 volunteers administered a single oral dose of 325 mg enteric coated or non-enteric coated aspirin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22248/abstract/23\">",
"     23",
"    </a>",
"    ]. Apparent nonresponse was common following enteric coated aspirin, but not non-enteric coated aspirin. All of the individuals with apparent nonresponse after initial dosing showed an adequate response to aspirin upon one of the following: change to non-enteric coated aspirin; administration of serial doses of enteric coated aspirin; or addition of aspirin to their platelets in vitro. The study thus failed to identify a single case of true aspirin resistance. This study supports our preference for non-enteric coated aspirin in the setting of acute thrombotic events to ensure a rapid clinical antithrombotic effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19401?source=see_link&amp;anchor=H437013703#H437013703\">",
"     \"Nonresponse and resistance to aspirin\", section on 'Use of enteric coated aspirin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H21#H21\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Aspirin formulation'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/1\">",
"      Brentjens RJ, Davila ML, Riviere I, et al. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. Sci Transl Med 2013; 5:177ra38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/2\">",
"      Grupp SA, Kalos M, Barrett D, et al. Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia. N Engl J Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/3\">",
"      Lo-Coco F, Avvisati G, Orlando SM, et al. ATRA and arsenic trioxide (ATO) versus ATRA and idarubicin (AIDA) for newly diagnosed, non high-risk acute promyelocytic leukemia (APL): Results of the phase III, prospective, randomized, intergroup APL0406 study by the Italian-German coperative groups Gimema-SAL-AMLSG (abstract 6). Blood 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/4\">",
"      Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30:2670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/5\">",
"      O'Brien S, Schiller G, Lister J, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol 2013; 31:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/6\">",
"      Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/7\">",
"      Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013; 368:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/8\">",
"      Macdougall IC, Provenzano R, Sharma A, et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013; 368:320.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm340895.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/10\">",
"      Woyach JA, Ruppert AS, Rai K, et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol 2013; 31:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/11\">",
"      Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013; 368:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/12\">",
"      Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/13\">",
"      Kim DW, Cortes J, Pinilla-Ibarz J, et al. Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial (abstract 3749). ASH Annual Meeting Abstracts 2012; 120:3749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/14\">",
"      Kantarjian HM, Kim DW, Pinilla-Ibarz J, et al. Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial (abstract 915). ASH Annual Meeting Abstracts 2012; 120:915.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf?et_cid=30657199&amp;et_rid=463648356&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f203469lbl.pdf (Accessed on December 17, 2012).",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf?et_cid=30334780&amp;et_rid=463648356&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f203585lbl.pdf (Accessed on October 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/17\">",
"      Cortes J, Lipton JH, Rea D, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 2012; 120:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/18\">",
"      Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012; 30:2820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/19\">",
"      Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013; 368:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/20\">",
"      de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012; 367:2305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/21\">",
"      Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/22\">",
"      Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/23\">",
"      Grosser T, Fries S, Lawson JA, et al. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation 2013; 127:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/24\">",
"      Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/25\">",
"      Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/26\">",
"      Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/27\">",
"      Warkentin TE. Aspirin for dual prevention of venous and arterial thrombosis. N Engl J Med 2012; 367:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/28\">",
"      Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/29\">",
"      Scholz CW, Pinto A, Linkesch W, et al. (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 2013; 31:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/30\">",
"      El-Galaly TC, d'Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 2012; 30:4508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/31\">",
"      Hentrich M, Berger M, Wyen C, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol 2012; 30:4117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/32\">",
"      Montoto S, Shaw K, Okosun J, et al. HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era. J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/33\">",
"      Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30:3452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/34\">",
"      Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30:3460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/35\">",
"      Wang ZY, Liu QF, Wang H, et al. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood 2012; 120:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/36\">",
"      Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstr&ouml;m macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol 2013; 31:301.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204026lbl.pdf?et_cid=31038989&amp;et_rid=463648356&amp;linkid=www.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2013%2f204026lbl.pdf (Accessed on February 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/38\">",
"      Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012; 120:4292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/39\">",
"      Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/40\">",
"      Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012; 380:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22248/abstract/41\">",
"      Simon J. Stanworth, Lise Estcourt, Gillian Powter, et al. The Effect of a No-Prophylactic Versus Prophylactic Platelet Transfusion Strategy On Bleeding in Patients with Hematological Malignancies and Severe Thrombocytopenia (TOPPS trial). A Randomized Controlled, Non-Inferiority Trial. American Society of Hematology abstract book 2012; 120:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8359 Version 2375.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.150-4095160E28-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_46_22248=[""].join("\n");
var outline_f21_46_22248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Chimeric antigen receptor-modified T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Arsenic trioxide plus ATRA for acute promyelocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Decitabine for acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Liposomal vincristine for acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ANEMIA AND OTHER RED CELL DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Erythropoiesis stimulating agents in heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Peginesatide, cardiovascular events, and drug withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CHRONIC LEUKEMIAS AND THE MYELOPROLIFERATIVE NEOPLASMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chlorambucil for older adults with chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      The optimal hematocrit in polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ponatinib for CML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Omacetaxine mepesuccinate for CML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nodal response in CLL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HEMATOPOIETIC CELL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chlorhexidine bathing for intensive care and hematopoietic cell transplant patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Expansion of umbilical cord blood in culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Peripheral blood progenitor cell versus bone marrow transplant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      HEMOSTASIS AND THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Risk of inhibitor development in patients with hemophilia A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Enteric coating affects aspirin absorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Apixaban for secondary prevention of venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Aspirin for secondary prevention of venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      LYMPHOMA: HODGKIN AND NON-HODGKIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Bendamustine plus rituximab in mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Bendamustine plus rituximab for newly diagnosed follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Anti-CD20 radioimmunoconjugates as initial therapy in follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Staging bone marrow biopsy in Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Hodgkin lymphoma in HIV infected patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      \"Double-hit\" lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      EBV-DNA levels in extranodal NK/T cell lymphoma, nasal type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      MULTIPLE MYELOMA AND OTHER PLASMA CELL DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Fludarabine versus chlorambucil for Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Pomalidomide for relapsed multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Monoclonal gammopathy of renal significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      TRANSFUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Blood transfusion thresholds for acute upper GI bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Prophylactic versus therapeutic platelet transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      OTHER HEMATOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Enteric coating affects aspirin absorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=related_link\">",
"      Diagnosis of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17671?source=related_link\">",
"      Evaluating response to treatment of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13594?source=related_link\">",
"      Evaluation and treatment of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=related_link\">",
"      Factor VIII and factor IX inhibitors in patients with hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1705?source=related_link\">",
"      Impact of anemia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=related_link\">",
"      Initial evaluation and diagnosis of Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=related_link\">",
"      Initial treatment of advanced stage (III/IV) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/63/17402?source=related_link\">",
"      Initial treatment of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19401?source=related_link\">",
"      Nonresponse and resistance to aspirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/33/33303?source=related_link\">",
"      Pomalidomide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28554?source=related_link\">",
"      Prognosis and treatment of polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29127?source=related_link\">",
"      Prognosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15865?source=related_link\">",
"      Selection of an umbilical cord blood graft for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6362?source=related_link\">",
"      Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37626?source=related_link\">",
"      Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=related_link\">",
"      Treatment of chronic myeloid leukemia in accelerated phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=related_link\">",
"      Treatment of chronic myeloid leukemia in blast crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=related_link\">",
"      Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21753?source=related_link\">",
"      Treatment of relapsed or refractory acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_46_22249="Hydrocortisone (systemic): Pediatric drug information";
var content_f21_46_22249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydrocortisone (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?8/48/8969?source=see_link\">",
"    see \"Hydrocortisone (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/36/35398?source=see_link\">",
"    see \"Hydrocortisone (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8116174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      A-Hydrocort&reg;;",
"     </li>",
"     <li>",
"      Cortef&reg;;",
"     </li>",
"     <li>",
"      Solu-CORTEF&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8116175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cortef&reg;;",
"     </li>",
"     <li>",
"      Solu-Cortef&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10820821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Systemic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Dose should be based on severity of disease and patient response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bronchopulmonary dysplasia, prevention (preterm neonates with prenatal inflammatory exposure):",
"     </b>",
"     PNA &le;48 hours: I.V.: 1 mg/kg/day divided every 12 hours for 9 or 12 days followed by 0.5 mg/kg/day divided every 12 hours for 3 days; low-dose (ie, physiologic replacement) has been shown to be effective at improving survival without BPD in chorioamnionitis-exposed ELBW neonates (birth weight: 500-999 g) (Watterberg, 1999; Watterberg, 2004; Watterberg, 2010); of note, a higher incidence of gastrointestinal perforation in the treatment arm resulted in early study closure of the largest trial (Watterberg, 2004). In another trial of VLBW neonates (PNA &le;36 hours, GA &lt;30 weeks, birth weight: 500-1250 g), higher dosages (ie, stress dose): 2 mg/kg/day divided every 8 hours for 2 days followed by 1.5 mg/kg/day divided every 8 hours for 2 days followed by 0.75 mg/kg/day divided every 12 hours for 6 days showed a trend in the treatment arm of decreased severity of respiratory failure, shorten length of oxygen therapy and promotion of PDA closure; this trial was closed early due to higher incidence of gastrointestinal perforation in the treatment arm versus placebo (Peltoniemi, 2005).",
"     <b>",
"      Note:",
"     </b>",
"     The AAP suggests that for neonates with prenatal inflammatory exposure, low-dose hydrocortisone therapy (1 mg/kg/day) during the first 2 weeks of life may improve survival without BPD and without adverse neurodevelopmental outcomes (Watterberg, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Congenital adrenal hyperplasia:",
"     </b>",
"     Oral [tablets (crushed)]: Initial: 10-15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 3 divided doses; higher initial doses (20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day) may be required to achieve initial target hormone serum concentrations. Administer morning dose as early as possible. Due to uneven distribution of the drug in the liquid, use of oral suspension is",
"     <b>",
"      not",
"     </b>",
"     recommended [AAP, 2000; Speiser (Endocrine Society), 2010]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypoglycemia, refractory (refractory to continuous glucose infusion of &gt;12-15 mg/kg/minute):",
"     </b>",
"     Oral, I.V.: 5 mg/kg/day divided every 8-12 hours or 1-2 mg/kg/",
"     <b>",
"      dose",
"     </b>",
"     every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypotension, refractory; shock:",
"     </b>",
"     I.V.: Limited data available; dosage regimens variable (Brierley, 2009; Higgins, 2010): 3 mg/kg/day divided every 8 hours for 5 days; dosing based on the largest, prospective, randomized, placebo-controlled trial of 48 hypotensive, VLBW neonates (PNA: &lt;7 days; GA: &lt;32 weeks; birth weight: &lt;1500 g) who were also receiving dopamine at doses &ge;10 mcg/kg/minute (Ng, 2006); other smaller trials have used 2 mg/kg/day divided every 12 hours for 1-3 days (Seri, 2001) or 2 mg/kg once, followed by 2 mg/kg/day divided every 12 hours for 4 doses (Noori, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10820953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/48/8969?source=see_link\">",
"      see \"Hydrocortisone (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose should be based on severity of disease and patient response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adrenal insufficiency (acute):",
"     </b>",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and young Children: 1-2 mg/kg/",
"     <b>",
"      dose",
"     </b>",
"     I.V. bolus, then 25-150 mg/day in divided doses every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Older Children: 1-2 mg/kg/",
"     <b>",
"      dose",
"     </b>",
"     I.V. bolus, then 150-250 mg/day in divided doses every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Anti-inflammatory or immunosuppressive:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: 2.5-10 mg/kg/day or 75-300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day divided every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M., I.V.: 1-5 mg/kg/day or 30-150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day divided every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents: Oral, I.M., I.V., SubQ: 15-240 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Congenital adrenal hyperplasia:",
"     </b>",
"     Oral (tablets): AAP Recommendations:",
"     <b>",
"      Note:",
"     </b>",
"     Administer morning dose as early as possible. Tablets may result in more reliable serum concentrations than oral liquid formulation; use of oral suspension is not recommended. Individualize dose by monitoring growth, hormone levels, and bone age; mineralocorticoid (eg, fludrocortisone) and sodium supplement may be required in salt losers (AAP, 2000; AAP, 2010; Endocrine Society, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: 10-15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 3 divided doses; higher initial doses (20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day) may be required to achieve initial target hormone serum concentrations (AAP, 2010; Endocrine Society, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance dose: Usual requirement:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants: 2.5-5 mg/",
"     <b>",
"      dose",
"     </b>",
"     3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: 5-10 mg/",
"     <b>",
"      dose",
"     </b>",
"     3 times/day;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Physiologic replacement:",
"     </b>",
"     Infants and Children: Oral: 8-10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day divided every 8 hours; up to 12 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in some patients (Ahmet, 2011; Gupta, 2008; Maguire, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Septic shock:",
"     </b>",
"     Infants, Children, and Adolescents: I.V.: Initial: 1-2 mg/kg/day (intermittent or as continuous I.V. infusion); doses may be titrated up to 50 mg/kg/day if necessary for shock reversal (Brierley, 2009); alternative dosing suggests 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (Dellinger, 2008);",
"     <b>",
"      Note:",
"     </b>",
"     Use recommended only in catecholamine-resistant shock and suspected or proven adrenal insufficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adrenal insufficiency (acute):",
"     </b>",
"     I.M., I.V.: 100 mg I.V. bolus, then 300 mg/day in divided doses every 8 hours or as a continuous infusion for 48 hours; once patient is stable, change to oral, 50 mg every 8 hours for 6 doses, then taper to 30-50 mg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adrenal insufficiency (chronic), physiologic replacement:",
"     </b>",
"     Oral: 15-25 mg/day in 2-3 divided doses.",
"     <b>",
"      Note:",
"     </b>",
"     Studies suggest administering one-half to two-thirds of the daily dose in the morning in order to mimic the physiological cortisol secretion pattern. If the twice-daily regimen is utilized, the second dose should be administered 6-8 hours following the first dose (Arlt, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Anti-inflammatory or immunosuppressive:",
"     </b>",
"     Oral, I.M., I.V.: 15-240 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Congenital adrenal hyperplasia:",
"     </b>",
"     Oral: 15-25 mg/day in 2-3 divided doses (Speiser, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Septic shock:",
"     </b>",
"     I.V.: 50 mg every 6 hours (Annane, 2002; Marik, 2008); not to exceed 300 mg/day (Dellinger, 2008). Practice guidelines also recommend alternative dosing of 100 mg bolus, followed by continuous infusion of 10 mg/hour (240 mg/day). Taper slowly (for total of 11 days) and do not stop abruptly.",
"     <b>",
"      Note:",
"     </b>",
"     Fludrocortisone is optional with use of hydrocortisone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Status asthmaticus:",
"     </b>",
"     I.V.: 1-2 mg/kg/dose every 6 hours for 24 hours, then maintenance of 0.5-1 mg/kg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Stress dosing (surgery) in patients known to be adrenally-suppressed or on chronic systemic steroids:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Minor stress (ie, inguinal herniorrhaphy): 25 mg/day for 1 day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Moderate stress (ie, joint replacement, cholecystectomy): 50-75 mg/day (25 mg every 8-12 hours) for 1-2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Major stress (pancreatoduodenectomy, esophagogastrectomy, cardiac surgery): 100-150 mg/day (50 mg every 8-12 hours) for 2-3 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8116380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium succinate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-Hydrocort&reg;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solu-CORTEF&reg;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium succinate [strength expressed as base, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solu-CORTEF&reg;: 100 mg, 250 mg, 500 mg, 1000 mg [supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as base: 5 mg, 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortef&reg;: 5 mg, 10 mg, 20 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8116180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10820961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer with food or milk to decrease GI upset",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Hydrocortisone sodium succinate may be administered by I.M. or I.V. routes. Dermal and/or subdermal skin depression may occur at the site of injection. Avoid injection into deltoid muscle (high incidence of SubQ atrophy); pH 7-8",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V. bolus: Dilute to 50 mg/mL and administer over at least 30 seconds; for large doses (&ge;500 mg in adults), administer over 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Intermittent I.V. infusion: Dilute to 1 mg/mL and administer over 20-30 minutes; usual maximum concentration: 5 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     In adult patients, when administration of a small volume of fluid is needed, concentrations up to 60 mg/mL (100-3000 mg in 50 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS) may be administered by direct I.V. or I.V. piggyback.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8116281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hydrocortisone sodium succinate:",
"     </b>",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      20",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS, fat emulsion 10%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, acyclovir, allopurinol, amifostine, aminophylline, amphotericin B cholesteryl sulfate complex, ampicillin, amsacrine, anidulafungin, argatroban, atracurium, atropine, aztreonam, betamethasone sodium phosphate, bivalirudin, calcium gluconate, caspofungin, cefepime, chlorpromazine, cisatracurium, cladribine, cyanocobalamin, cytarabine, dexamethasone sodium phosphate, dexmedetomidine, digoxin, diphenhydramine, docetaxel, dopamine, doripenem, doxorubicin liposome, droperidol, droperidol and fentanyl, edrophonium, enalaprilat, epinephrine, esmolol, estrogens (conjugated), ethacrynate sodium, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, fludarabine, fluorouracil, foscarnet, furosemide, gallium nitrate, gemcitabine, gold sodium thiosulfate, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydralazine, inamrinone, insulin (regular), isoproterenol, kanamycin, lidocaine, linezolid, lorazepam, magnesium sulfate, melphalan, meperidine, methylergonovine, minocycline, morphine, neostigmine, nicardipine, norepinephrine, ondansetron, oxacillin, oxaliplatin, oxytocin, paclitaxel, pancuronium, penicillin G potassium, pentazocine, phytonadione, piperacillin/tazobactam, procainamide, prochlorperazine edisylate, propofol, propranolol, pyridostigmine, remifentanil, scopolamine, sodium bicarbonate, succinylcholine, tacrolimus, telavancin, teniposide, theophylline, thiotepa, trimethobenzamide, vecuronium, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ciprofloxacin, diazepam, idarubicin, midazolam, phenytoin, sargramostim.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Antithymocyte globulin (rabbit), diltiazem, methylprednisolone sodium succinate, promethazine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dimenhydrinate, iohexol, iopamidol, iothalamate meglumine 60%, ioxaglate meglumine 39.3% and ioxaglate sodium 19.6%, methotrexate.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Doxapram, oxytocin, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cytarabine, magnesium sulfate, thiopental.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10820861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Store at controlled room temperature 20&deg;C to 25&deg;C (59&deg;F to 86&deg;F). Reconstituted solution is clear, light yellow and heat labile.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     After initial reconstitution, hydrocortisone sodium succinate solutions are stable for 3 days at room temperature or under refrigeration when protected from light. Stability of parenteral admixture (Solu-Cortef&reg;) at room temperature (25&deg;C) and at refrigeration temperature (4&deg;C) is concentration-dependent:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     1 mg/mL: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     2-60 mg/mL: At least 4 hours",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10820850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases, including those of allergic, hematologic, dermatologic, gastrointestinal, ophthalmic,  neoplastic, rheumatic, autoimmune, nervous system, renal, and respiratory origin [FDA approved in pediatric patients (age not specified) and adults]; primary or secondary adrenocorticoid deficiency (drug of choice) [FDA approved in pediatric patients (age not specified) and adults]; has also been used for management of septic shock and in neonates for treatment of hypotension and prevention of bronchopulmonary dysplasia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8116164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Hydrocortisone may be confused with hydrocodone, hydroxychloroquine, hydrochlorothiazide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cortef&reg; may be confused with Coreg&reg;, Lortab&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HCT (occasional abbreviation for hydrocortisone) is an error-prone abbreviation (mistaken as hydrochlorothiazide)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Solu-CORTEF&reg; may be confused with Solu-MEDROL&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8116248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, bradycardia, cardiac arrest, cardiomegaly, circulatory collapse, congestive heart failure, edema, fat embolism, hypertension, hypertrophic cardiomyopathy (premature infants), myocardial rupture (post MI), syncope, tachycardia, thromboembolism, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Delirium, depression, emotional instability, euphoria, hallucinations, headache, insomnia, intracranial pressure increased, malaise, mood swings, nervousness, neuritis, neuropathy, personality changes, pseudotumor cerebri, psychic disorders, psychoses, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, allergic dermatitis, alopecia, bruising, burning/tingling, dry scaly skin, edema, erythema, hirsutism, hyper-/hypopigmentation, impaired wound healing, petechiae, rash, skin atrophy, skin test reaction impaired, sterile abscess, striae, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Adrenal suppression, alkalosis, amenorrhea, carbohydrate intolerance increased, Cushing's syndrome, diabetes mellitus, glucose intolerance, growth suppression, hyperglycemia, hyperlipidemia, hypokalemia, hypokalemic alkalosis, menstrual irregularities, negative nitrogen balance, pituitary-adrenal axis suppression, potassium loss, protein catabolism, sodium and water retention, sperm motility increased/decreased, spermatogenesis increased/decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, appetite increased, bowel dysfunction (intrathecal administration), indigestion, nausea, pancreatitis, peptic ulcer, gastrointestinal perforation, ulcerative esophagitis, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Bladder dysfunction (intrathecal administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukocytosis (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatomegaly, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy (at injection site), postinjection flare (intra-articular use), thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, necrosis (femoral and humoral heads), Charcot-like arthropathy, fractures, muscle mass loss, muscle weakness, myopathy, osteoporosis, tendon rupture, vertebral compression fractures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts, exophthalmoses, glaucoma, intraocular pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Abnormal fat deposits, anaphylaxis, avascular necrosis, diaphoresis, hiccups, hypersensitivity reactions, infection, secondary malignancy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10820851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydrocortisone or any component; serious infections, except septic shock or tuberculous meningitis; viral, fungal, or tubercular skin lesions",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10820853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended doses; suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, hypercorticism (Cushing's syndrome), hyperglycemia, or glucosuria may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients by any route (monitor growth). Use with extreme caution in patients with respiratory tuberculosis or untreated systemic infections. Use with caution in patients with hypertension, heart failure, or renal impairment; long-term use has been associated with fluid retention and hypertension. High-dose corticosteroids should not be used for management of head injury; increased mortality was observed in patients receiving high-dose I.V. methylprednisolone. Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred, especially during initial treatment with corticosteroids. Use with caution in patients with hepatic impairment, including cirrhosis; enhanced pharmacologic effect due to decreased metabolism and long-term use has been associated with fluid retention. Use with caution following acute MI; corticosteroids have been associated with myocardial rupture. Hypertrophic cardiomyopathy has been reported in premature neonates.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Use with caution in patients with diabetes; corticosteroids may alter glucose regulation, leading to hyperglycemia. Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use; consider routine eye exams in chronic users. Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis. Use with caution in patients with thyroid dysfunction; changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid patients. Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered. Use with caution in patients with thromboembolic tendencies or thrombophlebitis.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10820852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypothalamic-pituitary-adrenal (HPA) suppression may occur, particularly in younger children or in patients receiving high doses for prolonged periods; acute adrenal insufficiency (adrenal crisis) may occur with abrupt withdrawal after long-term therapy or with stress; withdrawal and discontinuation of corticosteroids should be tapered slowly and carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Immunosuppression may occur; patients may be more susceptible to infections; prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral or fungal infections, activate latent opportunistic infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex; use caution in patients with a history of ocular herpes simplex. Corticosteroids should not be used for cerebral malaria or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause osteoporosis (at any age) or inhibition of bone growth in pediatric patients. Use with caution in patients with osteoporosis. In a population-based study of children, risk of fracture was shown to be increased with &gt;4 courses of corticosteroids; underlying clinical condition may also impact bone health and osteoporotic effect of corticosteroids (Leonard, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause GI bleeding or perforation. In premature neonates, reports of gastrointestinal perforation in the hydrocortisone treatment arm have resulted in the closure of two large BPD clinical trials (Peltoniemi, 2005; Watterberg, 2004); concomitant use with indomethacin or ibuprofen may increase the risk and should be avoided in this population (Seri, 2006). Use with caution in patients with GI disease (diverticulitis, peptic ulcer disease, ulcerative colitis).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use. Acute myopathy may occur with high doses, usually in patients with neuromuscular transmission disorders; myopathy may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed. Increased IOP may occur, especially with prolonged use; in children, increased IOP has been shown to be dose-dependent and produce a greater IOP in children &lt;6 years than older children (Lam, 2005). Rare cases of anaphylactoid reactions have been reported with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Manufacturer-supplied diluents for injection (eg, Solu-Cortef&reg;) contain benzyl alcohol which may cause allergic reactions in susceptible individuals; oral suspension contains benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of hydrocortisone products containing benzoic acid, benzyl alcohol, or benzyl benzoate in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8116271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8116272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10820855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic use of corticosteroids may require a diet with increased potassium, vitamins A, B",
"     <sub>",
"      6",
"     </sub>",
"     , C, D, folate, calcium, zinc, phosphorus, and decreased sodium",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8116218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8116219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Hydrocortisone crosses the placenta. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10820962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; weight; serum glucose; electrolytes; growth in pediatric patients; presence of infection, bone mineral density; assess HPA axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test). Monitor IOP with therapy &gt;6 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F10820963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hydrocortisone (normal endogenous morning levels): 4-30 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10820908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10820909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anti-inflammatory effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 8-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10820910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, biologic: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Renally, mainly as 17-hydroxysteroids and 17-ketosteroids",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10821085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/36/35398?source=see_link\">",
"      see \"Hydrocortisone (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not decrease dose or discontinue without physician&rsquo;s approval; dosage is usually tapered off gradually. Take oral dose with food to reduce GI upset. Avoid alcohol. Hydrocortisone may cause immunosuppression and mask symptoms of infection; avoid exposure to measles or chicken pox and notify prescriber if exposed or of any signs of infection (eg, fever, chills, sore throat, injury) and notify dentist or surgeon (if necessary) that you are taking this medication. You may experience increased appetite, indigestion, or increased nervousness. Report weight gain, swelling of extremities or respiratory difficulty, abdominal pain, severe vomiting, black or tarry stools, fatigue, anorexia, weakness, or unusual mood swings. Limit caffeine.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10821086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cortef&reg; oral suspension was reformulated in July 1998; the suspending agent was changed from tragacanth to xanthan gum; this suspension was found",
"     <b>",
"      not",
"     </b>",
"     to be bioequivalent to hydrocortisone tablets in the treatment of children with congenital adrenal hyperplasia; children required higher doses of the suspension (19.6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day) compared to the tablets (15.2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day); based on these findings, Cortef&reg; suspension was voluntarily recalled from the market on July 18, 2000 (Merke, 2001).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In premature neonates, the use of high-dose dexamethasone (approximately &gt;0.5 mg/kg/day) for the prevention or treatment of BPD has been associated with adverse neurodevelopmental outcomes, including higher rates of cerebral palsy without additional clinical benefit over lower doses; current data does not support use of high doses, further studies are needed (Watterberg, 2010). Data specific to hydrocortisone use in this population has shown that use &lt;7 days of therapy does not appear to be associated with adverse neurodevelopmental outcomes (Needelman, 2010).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hydrocortisone has been studied in children with cystic fibrosis and an ongoing lower respiratory tract infection using 2.5 mg/kg/",
"     <b>",
"      dose",
"     </b>",
"     every 6 hours for 10 days in addition to standard therapies. A double-blind, placebo- controlled trial of  22 infants and children (age: &lt;18 months; mean: 8.8-9.5 months) showed no significant difference in pulmonary function on day 10 of therapy between treatment and placebo groups; however, at 1-2 months after discharge, follow-up testing showed significant, sustained improvement of pulmonary function in the hydrocortisone group compared to placebo (Tepper, 1997). Further studies are needed and hydrocortisone is not recommended for routine use in current cystic fibrosis guidelines (Flume, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11585944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 2.5 mg/mL oral suspension may be made with either tablets or powder and a vehicle containing sodium carboxymethylcellulose (1 g), syrup BP (10 mL), hydroxybenzoate 0.1% preservatives (0.1 g), polysorbate 80 (0.5 mL), citric acid (0.6 g), and water. To make the vehicle, dissolve the hydroxybenzoate, citric acid, and syrup BP in hot water. Cool solution and add the carboxymethylcellulose; leave overnight. Crush twelve-and-one-half 20 mg hydrocortisone tablets (or use 250 mg of powder) in a mortar and reduce to a fine powder while adding polysorbate 80. Add small portions of vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add sufficient quantity of vehicle to make 100 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 90 days.",
"    </p>",
"    <div class=\"reference\">",
"     Fawcett JP, Boulton DW, Jiang R, et al, \"Stability of Hydrocortisone Oral Suspensions Prepared From Tablets and Powder,\"",
"     <i>",
"      Ann Pharmacother",
"     </i>",
"     , 1995, 29(10):987-90.",
"     <span class=\"pubmed-id\">",
"      8845559",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ahmet A, Kim H, and Spier S, \"Adrenal Suppression: A Practical Guide to the Screening and Management of this Under-Recognized Complication of Inhaled Corticosteroid Therapy,\"",
"      <i>",
"       Allergy Asthma Clin Immunol",
"      </i>",
"      , 2011, 7:13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/21867553/pubmed\" id=\"21867553\" target=\"_blank\">",
"        21867553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, \"Statement of Endorsement-Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(5):1051. Available at file://pediatrics.aappublications.org/cgi/content/extract/126/5/1051. Accessed May 10, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Section on Endocrinology and Committee on Genetics, \"Technical Report: Congenital Adrenal Hyperplasia,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 106(6):1511-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/11099616 /pubmed\" id=\"11099616 \" target=\"_blank\">",
"        11099616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Annane D, S&eacute;bille V, Charpentier C, et al, \"Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(7):862-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/12186604/pubmed\" id=\"12186604\" target=\"_blank\">",
"        12186604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arlt W and Allolio B, \"Adrenal Insufficiency,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9372):1881-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/12788587/pubmed\" id=\"12788587\" target=\"_blank\">",
"        12788587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker CF, Barks JD, Engmann C, et al, \"Hydrocortisone Administration for the Treatment of Refractory Hypotension in Critically Ill Newborns,\"",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 2008, 28(6):412-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/18337742/pubmed\" id=\"18337742\" target=\"_blank\">",
"        18337742",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brierley J, Carcillo JA, Choong K, et al, \"Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update From the American College of Critical Care Medicine,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2009, 37(2):666-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/19325359/pubmed\" id=\"19325359\" target=\"_blank\">",
"        19325359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carcillo JA and Fields AI, \"Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Patients in Septic Shock,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(6):1365-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/12072696/pubmed\" id=\"12072696\" target=\"_blank\">",
"        12072696",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cowett RM and Loughead JL, \"Neonatal Glucose Metabolism: Differential Diagnoses, Evaluation, and Treatment of Hypoglycemia,\"",
"      <i>",
"       Neonatal Netw",
"      </i>",
"      , 2002, 21(4):9-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/12078323/pubmed\" id=\"12078323\" target=\"_blank\">",
"        12078323",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, \"Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,\"",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2008, 34(1):17-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/18058085/pubmed\" id=\"18058085\" target=\"_blank\">",
"        18058085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flume PA, Mogayzel PJ Jr, Robinson KA, et al, \"Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations,\"",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2009, 180(9):802-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/19729669/pubmed\" id=\"19729669\" target=\"_blank\">",
"        19729669",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta P and Bhatia V, \"Corticosteroid Physiology and Principles of Therapy,\"",
"      <i>",
"       Indian J Pediatr",
"      </i>",
"      , 2008, 75(10):1039-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/19023528/pubmed\" id=\"19023528\" target=\"_blank\">",
"        19023528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Halamek LP and Stevenson DK, \"Neonatal Hypoglycemia, Part II: Pathophysiology and Therapy,\"",
"      <i>",
"       Clin Pediatr (Phila)",
"      </i>",
"      , 1998, 37(1):11-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/9475694/pubmed\" id=\"9475694\" target=\"_blank\">",
"        9475694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Han YY, Carcillo JA, Dragotta MA, et al, \"Early Reversal of Pediatric-Neonatal Septic Shock by Community Physicians is Associated With Improved Outcome,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2003, 112(4):793-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/14523168/pubmed\" id=\"14523168\" target=\"_blank\">",
"        14523168",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Higgins S, Friedlich P, and Seri I, \"Hydrocortisone for Hypotension and Vasopressor Dependence in Preterm Neonates: A Meta-Analysis,\"",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 2010, 30(6):373-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/19693023/pubmed\" id=\"19693023\" target=\"_blank\">",
"        19693023",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jain A, Aggarwal R, Jeevasanker M, et al, \"Hypoglycemia in the Newborn,\"",
"      <i>",
"       Indian J Pediatr",
"      </i>",
"      , 2008, 75(1):63-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/18245938/pubmed\" id=\"18245938\" target=\"_blank\">",
"        18245938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lam DS, Fan DS, Ng JS, et al, \"Ocular Hypertensive and Anti-Inflammatory Responses to Different Dosages of Topical Dexamethasone in Children: A Randomized Trial,\"",
"      <i>",
"       Clin Experiment Ophthalmol",
"      </i>",
"      , 2005, 33(3):252-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/15932528/pubmed\" id=\"15932528\" target=\"_blank\">",
"        15932528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leonard MB, \"Glucocorticoid-Induced Osteoporosis in Children: Impact of the Underlying Disease,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 119 Suppl 2:S166-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/17332238/pubmed\" id=\"17332238\" target=\"_blank\">",
"        17332238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maguire AM, Ambler GR, Moore B, et al, \"Prolonged Hypocortisolemia in Hydrocortisone Replacement Regimens in Adrenocorticotrophic Hormone Deficiency,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 120(1):164-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/17576782/pubmed\" id=\"17576782\" target=\"_blank\">",
"        17576782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marik PE, Pastores SM, Annane D, et al, \"Recommendations for the Diagnosis and Management of Corticosteroid Insufficiency in Critically Ill Adult Patients: Consensus Statements From an International Task Force by the American College of Critical Care Medicine,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(6):1937-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/18496365/pubmed\" id=\"18496365\" target=\"_blank\">",
"        18496365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Merke DP, Cho D, Calis KA, et al, \"Hydrocortisone Suspension and Hydrocortisone Tablets are not Bioequivalent in the Treatment of Children With Congenital Adrenal Hyperplasia,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2001, 86(1):441-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/11232038/pubmed\" id=\"11232038\" target=\"_blank\">",
"        11232038",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Needelman H, Hoskoppal A, Roberts H, et al, \"The Effect of Hydrocortisone on Neurodevelopmental Outcome in Premature Infants Less Than 29 Weeks' Gestation,\"",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 2010, 25(4):448-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/20139411/pubmed\" id=\"20139411\" target=\"_blank\">",
"        20139411",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ng PC, Lee CH, Bnur FL, et al, \"A Double-Blind, Randomized, Controlled Study of a 'Stress Dose' of Hydrocortisone for Rescue Treatment of Refractory Hypotension in Preterm Infants,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(2):367-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/16452355/pubmed\" id=\"16452355\" target=\"_blank\">",
"        16452355",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Noori S, Friedlich P, Wong P, et al, \"Hemodynamic Changes After Low-Dosage Hydrocortisone Administration in Vasopressor-Treated Preterm and Term Neonates,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 118(4):1456-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/17015536/pubmed\" id=\"17015536\" target=\"_blank\">",
"        17015536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peltoniemi O, Kari MA, Heinonen K, et al, \"Pretreatment Cortisol Values May Predict Responses to Hydrocortisone Administration for the Prevention of Bronchopulmonary Dysplasia in High-Risk Infants,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2005, 146(5):632-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/15870666/pubmed\" id=\"15870666\" target=\"_blank\">",
"        15870666",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seri I, \"Hydrocortisone and Vasopressor-Resistant Shock in Preterm Neonates,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(2):516-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/16452371/pubmed\" id=\"16452371\" target=\"_blank\">",
"        16452371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seri I, Tan R, and Evans J, \"Cardiovascular Effects of Hydrocortisone in Preterm Infants With Pressor-Resistant Hypotension,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 107(5):1070-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/11331688/pubmed\" id=\"11331688\" target=\"_blank\">",
"        11331688",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Speiser PW, Azziz R, Baskin LS, et al, \"Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2010, 95(9):4133-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/20823466/pubmed\" id=\"20823466\" target=\"_blank\">",
"        20823466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tepper RS, Eigen H, Stevens J, et al, \"Lower Respiratory Illness in Infants and Young Children With Cystic Fibrosis: Evaluation of Treatment With Intravenous Hydrocortisone,\"",
"      <i>",
"       Pediatr Pulmonol",
"      </i>",
"      , 1997, 24(1):48-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/9261853/pubmed\" id=\"9261853\" target=\"_blank\">",
"        9261853",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watterberg KL and American Academy of Pediatrics Committee on Fetus and Newborn, \"Policy Statement--Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(4):800-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/20819899/pubmed\" id=\"20819899\" target=\"_blank\">",
"        20819899",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watterberg KL, Gerdes JS, Cole CH, et al, \"Prophylaxis of Early Adrenal Insufficiency to Prevent Bronchopulmonary Dysplasia: A Multicenter Trial,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(6):1649-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/15574629/pubmed\" id=\"15574629\" target=\"_blank\">",
"        15574629",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watterberg KL, Gerdes JS, Gifford KL, et al, \"Prophylaxis Against Early Adrenal Insufficiency to Prevent Chronic Lung Disease in Premature Infants,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1999, 104(6):1258-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/46/22249/abstract-text/10585975/pubmed\" id=\"10585975\" target=\"_blank\">",
"        10585975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16001 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-218.189.88.190-50AA3700D9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_46_22249=[""].join("\n");
var outline_f21_46_22249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116174\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116175\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10820821\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442604\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10820953\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116380\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116180\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10820961\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116281\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10820861\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10820850\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116164\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116248\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10820851\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10820853\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10820852\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116271\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116272\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10820855\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116218\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116219\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10820962\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10820963\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10820908\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10820909\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10820910\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10821085\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10821086\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11585944\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16001\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16001|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/48/8969?source=related_link\">",
"      Hydrocortisone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/36/35398?source=related_link\">",
"      Hydrocortisone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/54/21352?source=related_link\">",
"      Hydrocortisone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/25/19861?source=related_link\">",
"      Hydrocortisone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/33/7702?source=related_link\">",
"      Hydrocortisone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_46_22250="Treatment of seasonal influenza in adults";
var content_f21_46_22250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of seasonal influenza in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/46/22250/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/46/22250/contributors\">",
"     Kimon C Zachary, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/46/22250/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/46/22250/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/46/22250/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/46/22250/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/46/22250/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seasonal influenza is an acute respiratory illness caused by influenza A or B viruses. Influenza occurs in outbreaks and epidemics worldwide, mainly during the winter season. Although acutely debilitating, influenza is usually a self-limited infection. However, it is associated with increased morbidity and mortality in certain high-risk populations.",
"   </p>",
"   <p>",
"    Two classes of antiviral drugs are available for the treatment and prevention of influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The neuraminidase inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      , which are active against both influenza A and B.",
"     </li>",
"     <li>",
"      The adamantanes,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"       rimantadine",
"      </a>",
"      , which are only active against influenza A. Due to a marked increase in resistant isolates, the Advisory Committee on Immunization Practices (ACIP) recommends that adamantanes",
"      <strong>",
"       not",
"      </strong>",
"      be used in the United States for the treatment of influenza, except in selected circumstances [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Choice of antiviral drug'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of these drugs in the treatment of seasonal influenza will be reviewed here. Their role in the prevention of seasonal influenza, treatment and prevention of 2009 pandemic H1N1 influenza and avian influenza, and treatment and prevention of influenza in children are discussed separately; the pharmacologic characteristics of the antiviral drugs used for influenza are also presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=see_link\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39032?source=see_link\">",
"     \"Treatment and prevention of avian influenza\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19640?source=see_link\">",
"     \"Pharmacology of antiviral drugs for influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BENEFITS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When initiated promptly, antiviral therapy can shorten the duration of influenza symptoms by one to three days; the benefit is greatest when given within the first 24 to 30 hours and in patients with fever at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/3-9\">",
"     3-9",
"    </a>",
"    ]. Little to no benefit has been demonstrated when treatment is initiated two days or more after the onset of uncomplicated influenza. However, a patient survey found that only 13 percent of patients called their clinician within 48 hours of the onset of influenza-like symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies have suggested that antiviral therapy reduces the severity and incidence of complications of influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/4,8,11-13\">",
"     4,8,11-13",
"    </a>",
"    ], the duration of hospitalization in patients with severe influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/14\">",
"     14",
"    </a>",
"    ], and influenza-associated mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. &nbsp;",
"    <br/>",
"   </p>",
"   <p>",
"    Studies of the use of antiviral therapy during the 2009 H1N1 influenza A pandemic are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NEURAMINIDASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     Zanamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    are moderately effective for the treatment of infections with susceptible viruses, reducing the duration and severity of symptoms particularly when treatment is initiated early after onset of symptoms. This was illustrated in a meta-analysis of 20 randomized trials that studied healthy adults in whom slight alleviation of influenza-like illness symptoms was reported for both oseltamivir and zanamivir use, provided that medication was started within 48 hours of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/9\">",
"     9",
"    </a>",
"    ]. The neuraminidase inhibitors also reduce the duration of shedding and viral titer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neither",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    nor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    has been well studied in patients with severe seasonal influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/3\">",
"     3",
"    </a>",
"    ]. Studies of the use of neuraminidase inhibitors for the treatment of 2009 pandemic H1N1 influenza A infection are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=see_link&amp;anchor=H412091#H412091\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39032?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and prevention of avian influenza\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Investigational neuraminidase inhibitors are discussed below. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Investigational approaches'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Efficacy of oseltamivir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    is orally administered and is available as a capsule or powder for liquid suspension. It has good bioavailability and is widely distributed in the body.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    has been demonstrated to shorten the duration of influenza symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/5,6,11,18-23\">",
"     5,6,11,18-23",
"    </a>",
"    ], and to reduce the duration of viral shedding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/17\">",
"     17",
"    </a>",
"    ]. Some studies have also shown that oseltamivir reduces illness severity and complication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. As discussed below, meta-analyses have provided contradictory results regarding reduction in influenza-related lower respiratory tract complications in healthy adults [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/13,23\">",
"     13,23",
"    </a>",
"    ]. The role of oseltamivir in the prevention of lower respiratory tract infection complications in adults remains controversial.",
"   </p>",
"   <p>",
"    Some studies have shown a mortality reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] and shorter length of hospitalization in patients with severe influenza treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In meta-analyses, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    reduced the median duration of symptoms by 0.9 days in otherwise healthy adults [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/23\">",
"     23",
"    </a>",
"    ] and by 0.4 days in elderly adults or patients with comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The range of findings in adults can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 60-center trial randomly assigned 627 healthy adults 18 to 65 years of age to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      (75 or 150 mg twice daily) or placebo for five days within 36 hours of the onset of suspected influenza [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/11\">",
"       11",
"      </a>",
"      ]. Sixty percent had laboratory-confirmed influenza. Both doses of oseltamivir led to a statistically significant reduction in illness duration of approximately one day compared with placebo. Oseltamivir also reduced illness severity scores and the incidence of clinician-diagnosed secondary complications (pneumonia, bronchitis, sinusitis, and otitis media).",
"     </li>",
"     <li>",
"      Comparable results were noted in a 51-center trial with 719 healthy adult patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/6\">",
"       6",
"      </a>",
"      ]. Among the 66 percent of patients with laboratory-confirmed influenza,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      significantly reduced the duration of illness by approximately one day in patients treated 24 to 36 hours after illness onset, and by 1.5 to 2 days in those treated within 24 hours of illness onset.",
"     </li>",
"     <li>",
"      A 2003 systematic review utilized data from 10 published and unpublished placebo-controlled trials to evaluate the effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      therapy on influenza-related lower respiratory tract complications [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/12\">",
"       12",
"      </a>",
"      ]. Among patients with proven influenza, oseltamivir significantly reduced the incidence of lower respiratory tract complications that required antibiotic use compared with placebo (4.6 versus 10.3 percent in all patients, 12.2 versus 18.5 percent in patients at risk for complications).",
"     </li>",
"     <li>",
"      In contrast to the 2003 systematic review described above [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/12\">",
"       12",
"      </a>",
"      ], the authors of a 2012 meta-analysis deliberately did not assess a possible effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      on influenza-related lower respiratory tract complications because they believed that the unpublished data available to them lacked sufficient detail to address this question [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/23\">",
"       23",
"      </a>",
"      ]. This meta-analysis was based upon unpublished clinical study reports of data from randomized trials and documents from regulatory agencies. However, a 2011 meta-analysis that reanalyzed the results from 11 randomized trials (including the 10 trials that were included in the 2003 systematic review and one trial that was published after the 2003 review) concluded that oseltamivir treatment reduces the risk of lower respiratory tract complications by 28 percent overall (95% CI 11-42%) and by 37 percent among patients with confirmed influenza infections (95% CI 18-52%) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/13\">",
"       13",
"      </a>",
"      ]. Although all 11 trials that were included in the analyses were funded by the manufacturer of oseltamivir, the 2011 meta-analysis was conducted by independent researchers who were given full access to the efficacy and safety data in the trials, access to the statisticians involved in the trials to answer data-related questions, and complete freedom to publish any results [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 2012 meta-analysis evaluated the efficacy of antivirals for the treatment of influenza in 74 observational studies; only a small subset of these studies was used in each analysis since only those that adjusted for confounders were included [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/24\">",
"       24",
"      </a>",
"      ]. In an analysis of three studies of hospitalized patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      appeared to reduce mortality (odds ratio [OR] 0.23, 95% CI 0.13-0.43). In an analysis of four studies, oseltamivir appeared to reduce hospitalization in outpatients (OR 0.75, 95% CI 0.66-0.89). In an analysis of six studies, oseltamivir appeared to reduce the duration of fever by 33 hours (95% CI 21-45 hours) compared with no antiviral therapy. Mortality, hospitalizations, intensive care unit admission, and respiratory failure were reduced when oseltamivir was started within 48 hours of onset of symptoms compared with later. The authors pointed out that the quality of the data in the observational studies was low or very low.",
"     </li>",
"     <li>",
"      Some studies, but not others, have shown that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      may be less effective in reducing clinical symptoms related to influenza B. In a prospective, multicenter study conducted in Japan, influenza A was documented in 1818 patients and influenza B in 1485 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/18\">",
"       18",
"      </a>",
"      ]. The duration from treatment initiation to resolution of fever was significantly longer for patients with influenza B than for influenza A (mean duration 65 versus 48 hours, respectively). In addition, after four to six days of oseltamivir therapy, the resolution rate was higher for influenza B than for influenza A (52 versus 16 percent) in a subset of 75 patients in whom viral isolation was performed. In contrast, in a study of 64 children with influenza infections treated with oseltamivir (34 with influenza A subtype H3N2, 11 with influenza A subtype H1N1, 19 with influenza B), there were no differences in the reduction of viral shedding or time to clearance of virus among viral subtypes [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies during the 2009 H1N1 influenza A pandemic generally showed similar findings. The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    during the 2009 H1N1 influenza A pandemic is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=see_link\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Efficacy of zanamivir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     Zanamivir",
"    </a>",
"    is administered by oral inhalation. Inhaled zanamivir is contraindicated in patients with underlying asthma or other chronic respiratory conditions. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An intravenous formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    is being evaluated in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/26-28\">",
"     26-28",
"    </a>",
"    ], and is available for compassionate use.",
"   </p>",
"   <p>",
"    In a 2003 meta-analysis of randomized trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    reduced the median duration of symptoms of laboratory-confirmed influenza by 1.3 days in otherwise healthy adults &le;65 years of age and by two days in adults &ge;65 years of age or patients with comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/5\">",
"     5",
"    </a>",
"    ]. Subsequent meta-analyses have shown similar benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/9,22\">",
"     9,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one trial, 417 otherwise healthy adults presenting with suspected influenza of not more than 48 hours duration were randomly assigned to inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    (10 mg twice daily for five days), inhaled and intranasal zanamivir (6.4 mg twice daily for five days), or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/7\">",
"     7",
"    </a>",
"    ]. Sixty-three percent of subjects had laboratory-confirmed influenza. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among those with laboratory-confirmed influenza,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      significantly shortened the median time to alleviation of all major symptoms by approximately one day compared with placebo (four versus five days).",
"     </li>",
"     <li>",
"      Among the infected patients who were febrile at presentation, the median time to alleviation of all major symptoms was even more pronounced compared with placebo (four versus seven days).",
"     </li>",
"     <li>",
"      Among the infected patients who began",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      within 30 hours of symptom onset, there was also a three day shortening of major symptoms (four versus seven days). In contrast, there was no benefit when zanamivir was started more than 30 hours after symptom onset.",
"     </li>",
"     <li>",
"      There was no added benefit in the group that received intranasal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      in combination with inhaled zanamivir.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a separate trial, 455 previously healthy subjects who were at least 12 years old and presented with suspected influenza of &le;36 hours duration were randomly assigned to inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    (10 mg twice daily) or placebo for five days [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/8\">",
"     8",
"    </a>",
"    ]. Eighty percent had laboratory-confirmed influenza. Among the patients with influenza who received zanamivir, the median duration of illness was significantly reduced by 1.5 days overall and by two days in those with fever at presentation. A subgroup of 39 patients, most of whom had mild asthma, was defined as high risk for complications of influenza. Zanamivir was associated with significantly fewer complications and a reduced need for antibiotics in this subgroup.",
"   </p>",
"   <p>",
"    Another trial also demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    shortens the duration of illness and reduces the symptoms of influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of neuraminidase inhibitors are typically mild, although more serious side effects have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/30\">",
"     30",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     Zanamivir",
"    </a>",
"    can cause bronchospasm and a decline in respiratory function in patients with asthma and other chronic respiratory disorders. As a result, the manufacturer has issued a warning advising particular caution in patients with asthma or chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     Zanamivir",
"    </a>",
"    inhalation powder is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for use in nebulizers or mechanical ventilators since the lactose carrier can clog ventilator tubing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2,32\">",
"     2,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19640?source=see_link&amp;anchor=H13#H13\">",
"     \"Pharmacology of antiviral drugs for influenza\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In November 2006, the manufacturer of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    notified healthcare professionals and the FDA of postmarketing reports of self-injury and delirium in patients (primarily children) receiving the drug for treatment of influenza. Most of these reports came from Japan, where the drug is used more commonly than in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/33\">",
"     33",
"    </a>",
"    ]. However, a subsequent study has not demonstrated a causal association between neuraminidase inhibitors and abnormal behavior, and Japan's health ministry is considering whether to modify the warning [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H7#H7\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Rare adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    can also cause nausea and vomiting, but these side effects have not generally resulted in discontinuation of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19640?source=see_link&amp;anchor=H9#H9\">",
"     \"Pharmacology of antiviral drugs for influenza\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ADAMANTANES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adamantanes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    , are active only against influenza A viruses, but high rates of resistance have developed and these drugs are infrequently indicated. These drugs prevent viral replication by blocking the viral M2 protein ion channel, which prevents fusion of the virus and host-cell membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39880?source=see_link\">",
"     \"Antiviral drug resistance among seasonal influenza viruses\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19640?source=see_link&amp;anchor=H11#H11\">",
"     \"Pharmacology of antiviral drugs for influenza\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Advisory Committee on Immunization Practices (ACIP) recommends that adamantanes (M2 inhibitors)",
"    <strong>",
"     not",
"    </strong>",
"    be used for the treatment of influenza in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2\">",
"     2",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    should be used for most cases of influenza that require treatment. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Neuraminidase inhibitors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18\">",
"     'Choice of antiviral drug'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69456256\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a 2006 meta-analysis that included trials of the adamantanes from the 1960s through the 1980s, prior to the emergence of substantial rates of resistance, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    reduced the duration of symptoms of influenza by about one day and reduced the severity of fever and other symptoms in patients with uncomplicated influenza A infections [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/4\">",
"     4",
"    </a>",
"    ]. In recent years, high levels of resistance to these agents have emerged, initially in Asia and more recently in North America. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39880?source=see_link&amp;anchor=H527125#H527125\">",
"     \"Antiviral drug resistance among seasonal influenza viruses\", section on 'Adamantane resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in young adults have reported a discontinuation rate of 13 to 17 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    , largely attributable to central nervous system toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     Rimantadine",
"    </a>",
"    causes fewer central nervous system side effects than amantadine (13 versus 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/36\">",
"     36",
"    </a>",
"    ] and has a discontinuation rate due to adverse effects that is similar to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19640?source=see_link&amp;anchor=H13#H13\">",
"     \"Pharmacology of antiviral drugs for influenza\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16530540\">",
"    <span class=\"h1\">",
"     RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although antiviral drug resistance among influenza viruses has occurred during antiviral therapy, resistant influenza strains have spread widely in the absence of such drug pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/38\">",
"     38",
"    </a>",
"    ]. As examples, adamantane-resistant H3N2 influenza A viruses have circulated globally since 2003,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    -resistant seasonal H1N1 influenza A viruses since 2007 (the H274Y mutation), and adamantane-resistant pandemic H1N1 influenza A viruses since 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/38\">",
"     38",
"    </a>",
"    ]. A mutation that confers low to moderate oseltamivir and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    resistance, the S247N mutation, has been detected in the Asia Pacific region since December 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/39\">",
"     39",
"    </a>",
"    ]. When combined with the H274N mutation, the dual",
"    <span class=\"nowrap\">",
"     S247N/H275Y",
"    </span>",
"    mutant can cause high-level resistance to oseltamivir and zanamivir. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39880?source=see_link\">",
"     \"Antiviral drug resistance among seasonal influenza viruses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since September 2009, 99 percent of influenza virus isolates tested in the US have been susceptible to neuraminidase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2,40,41\">",
"     2,40,41",
"    </a>",
"    ]. Information regarding antiviral resistance that emerges during the influenza season is available through the",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/professionals\">",
"     United States Centers for Disease Control and Prevention",
"    </a>",
"    (CDC). Clinicians should review antiviral resistance patterns and the CDC&rsquo;s web site for updated antiviral recommendations should increased resistance emerge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ANTIVIRAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Advisory Committee on Immunization Practices (ACIP) published updated guidelines for the use of antivirals for patients with confirmed or suspected influenza virus infection (caused by either pandemic H1N1 or seasonal strains) in January 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2\">",
"     2",
"    </a>",
"    ], and a summary of antiviral recommendations was released by the CDC in August 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/42\">",
"     42",
"    </a>",
"    ]. Our recommendations reflect those of the ACIP and CDC. See the",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/professionals/antivirals/index.htm\">",
"     CDC's web site",
"    </a>",
"    for updated recommendations. Clinicians in other countries should consult with their ministries of health",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the World Health Organization for specific recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Target populations for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with severe disease (requiring hospitalization or evidence of lower respiratory tract infection) or at high risk for complications should receive antiviral therapy. Antiviral therapy, when indicated, should be initiated as promptly as possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Definition of high risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults at high risk for complications for influenza include (",
"    <a class=\"graphic graphic_table graphicRef72029 \" href=\"UTD.htm?32/50/33579\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2,43\">",
"     2,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Residents of nursing homes and other chronic care facilities",
"     </li>",
"     <li>",
"      Adults &ge;65 years of age",
"     </li>",
"     <li>",
"      Pregnant women and women up to two weeks postpartum [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/44\">",
"       44",
"      </a>",
"      ]. The risk of complicated influenza during pregnancy increases by trimester and with associated comorbidities [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Target populations for treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Pregnancy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Individuals with chronic medical conditions including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pulmonary disease, including asthma (particularly if systemic glucocorticoids have been required during the past year)",
"     </li>",
"     <li>",
"      Cardiovascular disease, except isolated hypertension",
"     </li>",
"     <li>",
"      Active malignancy",
"     </li>",
"     <li>",
"      Chronic renal insufficiency",
"     </li>",
"     <li>",
"      Chronic liver disease",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Hemoglobinopathies such as sickle cell disease",
"     </li>",
"     <li>",
"      Immunosuppression, including HIV infection (particularly if CD4 &lt;200",
"      <span class=\"nowrap\">",
"       cells/microL),",
"      </span>",
"      organ or hematopoietic cell transplantation, inflammatory disorders treated with immunosuppressants",
"     </li>",
"     <li>",
"      Any neurologic condition that can compromise handling of respiratory secretions (eg, cognitive dysfunction, spinal cord injuries, seizure disorders, neuromuscular disorders)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Native Americans and Alaska Natives",
"     </li>",
"     <li>",
"      Individuals who are morbidly obese (body-mass index [BMI] &ge;40)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a large cohort study, obese individuals (including those who were not morbidly obese) were more likely than non-obese individuals to be hospitalized for a respiratory illness during influenza season (BMI 30 to 34.9: 1.45 [95% 1.03-2.05]; BMI &ge;35: 2.12 [95% 1.45-3.10]) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/47\">",
"     47",
"    </a>",
"    ]. Among individuals with a BMI &ge;35, the association was present both for those without previously identified risk factors for severe influenza (OR 5.10, 95% 2.53-10.24) and for those with one previously identified risk factor (OR 2.11, 95% 1.10-4.06). Obesity was first identified as a risk factor for severe influenza during the 2009-2010 H1N1 influenza pandemic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/2/31786?source=see_link&amp;anchor=H26#H26\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\", section on 'Obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of the groups described above, those at highest risk for influenza complications may be those with underlying lung disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe immunosuppression (eg, lung transplant recipients, individuals with advanced HIV infection [CD4 &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL]).",
"    </span>",
"   </p>",
"   <p>",
"    Antiviral treatment should be considered in asplenic patients. Although there are no data regarding the risk for severe or complicated influenza among asplenic individuals, influenza is a risk factor for secondary bacterial infections that can cause severe disease among such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In accordance with the ACIP&rsquo;s guidelines, we recommend prompt initiation of antiviral therapy for individuals with suspected or confirmed influenza infection and",
"    <strong>",
"     any",
"    </strong>",
"    of the following features [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Illness requiring hospitalization",
"     </li>",
"     <li>",
"      Progressive, severe, or complicated illness, regardless of previous health or vaccination status (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\", section on 'Definitions of illness severity'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Risk factors for influenza complications, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age &ge;65 years",
"     </li>",
"     <li>",
"      Pregnant women and women up to two weeks postpartum (including those who have had pregnancy loss) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/44\">",
"       44",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Pregnancy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Individuals with certain medical conditions (",
"      <a class=\"graphic graphic_table graphicRef72029 \" href=\"UTD.htm?32/50/33579\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Definition of high risk'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients with the risk factors described above, including those with mild illness not requiring hospitalization, should be treated with antiviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adults with mild illness without high risk conditions who are younger than 65 years of age do",
"    <strong>",
"     not",
"    </strong>",
"    require testing or treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2\">",
"     2",
"    </a>",
"    ]. If such individuals present within the first 48 hours of illness, antiviral treatment can be considered in order to reduce the duration of illness, but those who present &gt;48 hours after illness onset should",
"    <strong>",
"     not",
"    </strong>",
"    be treated with antivirals since they are unlikely to benefit.",
"   </p>",
"   <p>",
"    Patients who are recovering from influenza generally do not require antiviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2\">",
"     2",
"    </a>",
"    ]. The decision of whether to initiate antiviral therapy for each patient should be based upon the clinician's judgment and on what is known about the potential benefits of therapy for seasonal influenza versus the potential risks. Given the concerning trends of increasing resistance with both the adamantanes and the neuraminidase inhibitors, the risk of promoting antiviral drug resistance should be considered when deciding which patients to treat. Overuse of the neuraminidase inhibitors, which are the agents of choice for the prevention and treatment of influenza, will promote further development of resistance that could lead to these agents becoming ineffective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Timing of antiviral initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should be initiated as soon as possible since antiviral therapy is most likely to provide benefit when initiated within the first 48 hours of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2,49\">",
"     2,49",
"    </a>",
"    ]. Treatment should not be delayed while awaiting the results of diagnostic testing, nor should it be withheld in patients with indications for therapy who present &gt;48 after the onset of symptoms, particularly among patients requiring hospitalization. Furthermore, patients who have a negative rapid antigen test for influenza but in whom the clinical suspicion for influenza infection is high should be treated with antivirals since the sensitivity of these tests is generally low. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5528?source=see_link\">",
"     \"Diagnosis of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with mild uncomplicated influenza infections who do not have risk factors for severe or complicated illness are not likely to benefit from antiviral therapy if it is initiated more than 48 hours after symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Choice of antiviral drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to assess the risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    -resistant influenza before choosing therapy for patients with influenza. Clinicians should review local or state influenza surveillance data weekly to determine which types of influenza (A or B) and subtypes of influenza A (H1N1 or H3N2) are circulating [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Influenza activity'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Oseltamivir resistance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients suspected of having influenza in whom treatment is indicated, we recommend treatment with a neuraminidase inhibitor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    ), provided that oseltamivir-resistant influenza is not suspected (",
"    <a class=\"graphic graphic_table graphicRef50350 \" href=\"UTD.htm?14/32/14860\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since July 2011, the United States Centers for Diseases Control and Prevention has reported cases of H3N2 variant (H3N2v) influenza A infection caused by reassortment of swine-origin H3N2 influenza A viruses and pandemic H1N1 influenza A viruses, most of which have occurred since July 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. Almost all patients reported direct or indirect contact with swine, and the majority attended fairs where swine were present. H3N2v influenza viruses are susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    , but resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/54\">",
"     54",
"    </a>",
"    ]. The indications for antiviral therapy for patients with H3N2v influenza infection are the same as for patients with seasonal influenza infection.",
"    <br/>",
"    <br/>",
"    The epidemiology of H3N2v influenza infection is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link&amp;anchor=H104949276#H104949276\">",
"     \"Epidemiology of influenza\", section on 'H3N2 variant influenza'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H398832\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    for the treatment of influenza is 75 mg orally twice daily and of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    is 10 mg [2 inhalations] twice daily (",
"    <a class=\"graphic graphic_table graphicRef50350 \" href=\"UTD.htm?14/32/14860\">",
"     table 2",
"    </a>",
"    ). Since oseltamivir is primarily excreted by the kidneys, dosing must be modified for renal insufficiency.",
"   </p>",
"   <p>",
"    Doubling the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    to 150 mg orally twice daily has been suggested for some severely ill patients with H5N1 avian influenza and was also suggested for certain severely ill patients (eg, immunocompromised hosts) during the H1N1 influenza pandemic [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The effectiveness of increased dosing of oseltamivir for seasonal influenza has not been proven, but limited data suggest that it is well-tolerated and may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2,57,58\">",
"     2,57,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39032?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and prevention of avian influenza\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Oseltamivir resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    -resistant seasonal H1N1 influenza A viruses emerged in 2007 and were present at high rates worldwide during the 2008 to 2009 influenza season, prior to the onset of the 2009 H1N1 influenza A (&ldquo;swine influenza&rdquo;) pandemic. The pandemic strain of H1N1 influenza A was generally susceptible to oseltamivir, except for sporadic cases of oseltamivir resistance. Since September 2009, 99 percent of influenza virus isolates tested in the US have been susceptible to neuraminidase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2,40,41\">",
"     2,40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39880?source=see_link&amp;anchor=H527111#H527111\">",
"     \"Antiviral drug resistance among seasonal influenza viruses\", section on 'Oseltamivir resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The IV formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    is being evaluated in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/28\">",
"     28",
"    </a>",
"    ], and is available for compassionate use from its manufacturer through an emergency investigational new drug application to the Food and Drug Administration. IV zanamivir was the recommended antiviral treatment for severely ill patients with highly suspected or confirmed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    -resistant 2009 pandemic H1N1 influenza A infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2\">",
"     2",
"    </a>",
"    ]. IV zanamivir is also the most appropriate therapy for patients with non-pandemic strains of oseltamivir-resistant H1N1 influenza A infection who require treatment but cannot tolerate inhaled zanamivir.",
"   </p>",
"   <p>",
"    Information regarding antiviral resistance that emerges during the influenza season is available through the",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/professionals\">",
"     United States Centers for Disease Control and Prevention",
"    </a>",
"    (CDC). Clinicians should review antiviral resistance patterns and the CDC&rsquo;s web site for updated antiviral recommendations should increased resistance emerge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H847204507\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended duration of antiviral therapy is five days [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/2\">",
"     2",
"    </a>",
"    ]. However, a longer duration of therapy can be considered in severely ill patients or immunosuppressed individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza causes more severe disease and an increased rate of mortality among pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/44\">",
"     44",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    are Pregnancy Category C drugs, reflecting that clinical studies have not been done to assess the safety of their use during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/59\">",
"     59",
"    </a>",
"    ]. No adverse events have been shown to be caused by oseltamivir or zanamivir among women who received these agents during pregnancy or among infants who were exposed while in utero, although there are limited data [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19640?source=see_link&amp;anchor=H14#H14\">",
"     \"Pharmacology of antiviral drugs for influenza\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnant women who meet current case definitions for confirmed, probable, or suspected influenza A infection should receive antiviral therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    , since the potential benefit outweighs the theoretical risk to the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/44\">",
"     44",
"    </a>",
"    ]. Oseltamivir is recommended over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    because only the former agent is systemically absorbed (",
"    <a class=\"graphic graphic_table graphicRef50350 \" href=\"UTD.htm?14/32/14860\">",
"     table 2",
"    </a>",
"    ). In addition, zanamivir is relatively contraindicated in patients with asthma or chronic obstructive pulmonary disease.",
"   </p>",
"   <p>",
"    Treatment should be initiated as early as possible, and should not be withheld while awaiting results of diagnostic testing or in situations in which testing is not performed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/44\">",
"     44",
"    </a>",
"    ]. Although the benefits of antiviral therapy are expected to be greatest when initiated within the first 48 hours following symptom onset, treatment should be administered even to pregnant women who present &gt;48 hours after illness onset, particularly in those requiring hospitalization.",
"   </p>",
"   <p>",
"    In addition to antiviral therapy, control of fever with antipyretic therapy is important when, since hyperthermia during the first trimester has been associated with neural tube defects and other birth defects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/45,61\">",
"     45,61",
"    </a>",
"    ]. In addition, fever during labor is a risk factor for neonatal seizures, encephalopathy, cerebral palsy, and neonatal death [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Symptom management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The management of influenza infection in pregnant women is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=see_link&amp;anchor=H5795703#H5795703\">",
"     \"Influenza and pregnancy\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of antivirals in hematopoietic cell transplant (HCT) recipients has not been studied in randomized trials. A retrospective review of laboratory-confirmed influenza cases in HCT recipients found that 62 of 4797 patients (1.3 percent) were diagnosed with influenza within 120 days of undergoing HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/62\">",
"     62",
"    </a>",
"    ]. Of the 51 patients who were initially diagnosed with upper respiratory tract involvement and no signs or symptoms suggesting pneumonia, 6 of 34 untreated patients developed pneumonia, whereas none of nine patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and one of eight patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    developed pneumonia.",
"   </p>",
"   <p>",
"    HCT recipients should be treated for influenza according to the recommendations for patients at high risk for influenza complications described above. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Indications for treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several investigational approaches for the treatment of influenza. These approaches include combination antiviral therapy with more than one agent, parenteral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    long-acting formulations of neuraminidase inhibitors, and antiviral agents with novel mechanisms of action. One modeling study suggested that combination antiviral therapy might improve outcomes from influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/63\">",
"     63",
"    </a>",
"    ]; however, clinical trials showing benefit of this approach are necessary before it can be recommended. Some experts have called for the use of primary virologic endpoints in the evaluation of new influenza therapies, particularly in patients with severe influenza infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in those at high risk of severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parenteral formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    , and another neuraminidase inhibitor, peramivir, have been developed and are considered investigational [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/26-28,65-68\">",
"     26-28,65-68",
"    </a>",
"    ]. Although none of these agents have been approved by the US Food and Drug Administration (FDA) as an IV formulation, the FDA issued an emergency use authorization (EUA) for the use of peramivir during the 2009 H1N1 influenza A pandemic, and intravenous zanamivir was also available for compassionate use from its manufacturer through an emergency investigational new drug (IND) application. Although the EUA for IV peramivir expired in June 2010, IV zanamivir remains available for compassionate use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=see_link&amp;anchor=H414876#H414876\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\", section on 'Antiviral agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a multinational trial, 1091 adults with seasonal influenza A or B virus infection were randomly assigned to receive either a single intravenous infusion of peramivir (300 or 600 mg) or oral administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    (75 mg twice a day for five days) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/69\">",
"     69",
"    </a>",
"    ]. The median duration of influenza symptoms was 78, 81, and 82 hours in the groups treated with 300 mg of peramivir, 600 mg of peramivir, or oseltamivir, respectively. Both doses of peramivir were considered to be noninferior to oseltamivir. The overall incidence of adverse drug reactions was significantly lower in the 300 mg peramivir group than in the other groups, but the incidence of severe reactions in either peramivir group was similar to that in the oseltamivir group.",
"   </p>",
"   <p>",
"    Although this trial suggests that 300 mg of peramivir is as effective as 600 mg of peramivir, in a trial by the same group that compared different doses of peramivir (600 mg or 300 mg IV daily of peramivir for one to five days) in 37 high-risk patients (with immunocompromise, chronic respiratory disease, or diabetes) with influenza infection, the duration of illness was shorter among those who received the 600 mg dosing compared with the 300 mg dosing (median duration of 42 versus 114 hours; hazard ratio 0.50, 95% CI 0.25-0.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/70\">",
"     70",
"    </a>",
"    ]. This trial suggests that a 600 mg dose of peramivir may be more effective than a 300 mg dose in high-risk patients, although a larger trial is necessary to confirm these findings.",
"   </p>",
"   <p>",
"    Long-acting neuraminidase inhibitors, which could allow a single dose to replace a five-day course, are also being developed, as illustrated by the following trials [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/67,71,72\">",
"     67,71,72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, a single inhalation of a long-acting neuraminidase inhibitor, laninamivir octanoate, was non-inferior to a five-day course of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      in adults with seasonal influenza [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/72\">",
"       72",
"      </a>",
"      ]. The median time to alleviation of illness was 73 hours among those who received 40 mg of laninamivir compared with 86 hours among those who received 20 mg of laninamivir and 74 hours among those who received oseltamivir. The proportion of patients shedding influenza virus at day 3 was significantly lower among those who received 40 mg of laninamivir compared with oseltamivir.",
"     </li>",
"     <li>",
"      Because peramivir has strong and prolonged affinity for influenza virus neuraminidase, the efficacy of a single dose of IV peramivir has been evaluated [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/73\">",
"       73",
"      </a>",
"      ]. In a randomized trial that included 300 previously healthy adults with proven infection with seasonal influenza who presented within 48 hours of symptom onset, a single dose of 300 mg or 600 mg of IV peramivir significantly reduced the time to alleviation of symptoms compared with placebo (hazard ratio 0.68 and 0.67, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    is a nucleoside analog that has in vitro activity against both influenza A and B viruses. However, clinical data regarding its efficacy have been inconclusive; thus, it is not recommended for the treatment of influenza infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other agents that have shown promise in animal models",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    humans include conjugated sialidase, hemagglutinin inhibitors, small interfering RNA, polymerase inhibitors, protease inhibitors, monoclonal antibodies, and a sphingosine analog [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/26,67,75-82\">",
"     26,67,75-82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been hypothesized that the antiinflammatory effects of statins could reduce the severity of illness associated with influenza infection, although this has not been established. In a surveillance study of 3043 hospitalized patients with laboratory-confirmed seasonal influenza infection in the United States, the 1013 patients who were receiving a statin had a lower likelihood of dying than those who were not (adjusted odds ratio 0.59, CI 0.38-0.92) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/83\">",
"     83",
"    </a>",
"    ], although confounding factors may have been present. Randomized trials are necessary to determine whether statins result in a survival benefit in patients with influenza infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link&amp;anchor=H5#H5\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\", section on 'Reduced inflammation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SYMPTOM MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    or nonsteroidal antiinflammatory drugs (NSAIDs) can be used to treat fever, headache, and myalgia associated with influenza. The use of salicylates should be avoided, particularly in children below 18 years of age, because of the association with Reye syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22506?source=see_link&amp;anchor=H28202936#H28202936\">",
"     \"Acute toxic-metabolic encephalopathy in children\", section on 'Reye syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cough suppressants are generally not recommended, especially for children as the cough is self-limited in most cases and does not require specific therapy. Patients should be advised to maintain hydration. Activity may need to be modified, based on patient symptoms, but can be resumed as tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ANTIBIOTICS FOR SECONDARY COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics are indicated only for bacterial complications of acute influenza such as bacterial pneumonia, otitis media, or sinusitis.",
"   </p>",
"   <p>",
"    The choice of antibiotics for pneumonia should be guided by Gram stain and culture of sputum. If the etiology of the pneumonia is not clear from the sputum examination, empiric antibiotics effective against the most common bacterial pathogens following influenza (ie, Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus) should be used. Examples include a third-generation cephalosporin (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ) or an extended-spectrum quinolone (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ) in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    if the index of suspicion for S. aureus is high. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     INFECTION CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with influenza who are managed as outpatients should remain home from work, school, and other populated environments until influenza signs and symptoms have abated. Infection control measures at home may be beneficial. A randomized trial found that the combination of hand hygiene and face masks, when implemented within 36 hours of symptom onset in the index patient, prevents the household transmission of seasonal influenza (adjusted odds ratio 0.33, 95% CI 0.13 to 0.87) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/46/22250/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection control measures for healthcare settings are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2599?source=see_link\">",
"     \"Infection control measures to prevent seasonal influenza in healthcare settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     INFLUENZA ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Centers for Disease Control and Prevention (CDC), in collaboration with the World Health Organization (WHO) and its reporting network, tracks influenza virus isolates throughout the world to monitor disease activity and antiviral resistance patterns, and to predict the appropriate components for the annual influenza vaccine. This information, which is updated weekly during influenza season, is available via the CDC through its",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/weekly\">",
"     website",
"    </a>",
"    . In addition, FluNet, a database for global influenza virus surveillance, is available via the",
"    <a class=\"external\" href=\"file://www.who.int/influenza/gisrs_laboratory/flunet/en/\">",
"     WHO website",
"    </a>",
"    . The typical trends of influenza activity in the United States are shown in the following figure (",
"    <a class=\"graphic graphic_figure graphicRef60877 \" href=\"UTD.htm?12/3/12349\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=see_link\">",
"       \"Patient information: Flu (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=see_link\">",
"       \"Patient information: Influenza symptoms and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Target groups for therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given the concerning trends of increasing resistance with both the adamantanes and the neuraminidase inhibitors, the risk of promoting antiviral drug resistance should be considered when deciding which patients to treat. Individuals with severe disease (requiring hospitalization or evidence of lower respiratory tract infection) or at high risk for complications should receive antiviral therapy. Antiviral therapy, when indicated, should be initiated as promptly as possible. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Target populations for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend antiviral therapy (with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      ) for all individuals with confirmed or suspected influenza virus infection who are severely ill, such as those with lower respiratory tract infection (eg, dyspnea, tachypnea, unexplained oxygen desaturation), and those who are showing signs of rapid clinical deterioration; we recommend treatment for such patients whether they present early in the course of infection (&lt;48 hours after symptom onset) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ), or later (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Indications for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend antiviral therapy for outpatients who present within 48 hours of symptom onset with confirmed or suspected influenza infection",
"      <strong>",
"       and",
"      </strong>",
"      who are at increased risk for complications (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We also recommend antiviral therapy for outpatients who present &gt;48 hours after symptom onset with confirmed or suspected influenza infection",
"      <strong>",
"       and",
"      </strong>",
"      who are at increased risk for complications provided that they are not yet improving (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Indications for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest antiviral therapy for patients who present within 48 hours of symptom onset with mild illness and who are not at increased risk for complications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). There is high quality evidence for benefit to the individual patient; however, there is only low quality evidence regarding the magnitude of the risk of promoting resistance, which remains a major concern. Additionally, when supplies are limited, antivirals should be reserved for high-risk patients. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Indications for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with uncomplicated influenza who have had more than 48 hours of influenza signs and symptoms",
"      <strong>",
"       not",
"      </strong>",
"      be treated with antivirals (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Indications for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treating all pregnant women with suspected or confirmed influenza, even those who present &gt;48 hours after onset of symptom onset provided that they are not yet improving (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Pregnancy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=see_link&amp;anchor=H5795703#H5795703\">",
"       \"Influenza and pregnancy\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Choice of antiviral agent",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinicians should review local or state influenza surveillance data during influenza season to determine which types of influenza (A or B) and subtypes of influenza A (H1N1 or H3N2) are circulating, as well as antiviral resistance patterns. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Choice of antiviral drug'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Influenza activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A neuraminidase inhibitor (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      ) is the recommended antiviral agent for the treatment of patients with influenza infection (",
"      <a class=\"graphic graphic_table graphicRef50350 \" href=\"UTD.htm?14/32/14860\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Choice of antiviral drug'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The recommended dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      is 10 mg [two inhalations] twice daily; the recommended dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      is 75 mg twice daily. Since oseltamivir is primarily excreted by the kidneys, dosing must be modified in the setting of renal insufficiency. The recommended duration of therapy for either drug is five days. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Choice of antiviral drug'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the high rates of influenza isolates resistant to adamantanes in the United States and in many other countries,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"       rimantadine",
"      </a>",
"      are not recommended for the treatment of influenza. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Choice of antiviral drug'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/1\">",
"      Glezen WP. Clinical practice. Prevention and treatment of seasonal influenza. N Engl J Med 2008; 359:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/2\">",
"      Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/3\">",
"      Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/4\">",
"      Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults: systematic review. Lancet 2006; 367:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/5\">",
"      Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003; 326:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/6\">",
"      Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/7\">",
"      Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997; 337:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/8\">",
"      Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet 1998; 352:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/9\">",
"      Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009; 339:b5106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/10\">",
"      Gaglia MA Jr, Cook RL, Kraemer KL, Rothberg MB. Patient knowledge and attitudes about antiviral medication and vaccination for influenza in an internal medicine clinic. Clin Infect Dis 2007; 45:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/11\">",
"      Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/12\">",
"      Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/13\">",
"      Hern&aacute;n MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011; 53:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/14\">",
"      Lee N, Chan PK, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007; 12:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/15\">",
"      McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/16\">",
"      Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc 2002; 50:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/17\">",
"      Aoki FY, Boivin G. Influenza virus shedding: excretion patterns and effects of antiviral treatment. J Clin Virol 2009; 44:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/18\">",
"      Kawai N, Ikematsu H, Iwaki N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 2006; 43:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/19\">",
"      Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/20\">",
"      Kawai N, Ikematsu H, Iwaki N, et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin Infect Dis 2005; 40:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/21\">",
"      Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/22\">",
"      Burch J, Corbett M, Stock C, et al. Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/23\">",
"      Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2012; 1:CD008965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/24\">",
"      Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 2012; 156:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/25\">",
"      Stephenson I, Democratis J, Lackenby A, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis 2009; 48:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/26\">",
"      Ong AK, Hayden FG. John F. Enders lecture 2006: antivirals for influenza. J Infect Dis 2007; 196:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/27\">",
"      Calfee DP, Peng AW, Cass LM, et al. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 1999; 43:1616.",
"     </a>",
"    </li>",
"    <li>",
"     Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital (NAI113678). file://clinicaltrials.gov/ct2/show/NCT01014988?term=NAI113678&amp;rank=1 (Accessed on October 08, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/29\">",
"      Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis 1999; 180:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/30\">",
"      Drugs for non-HIV viral infections. Treat Guidel Med Lett 2007; 5:59.",
"     </a>",
"    </li>",
"    <li>",
"     Relenza dear doctor letter in EU follow U.S. advisory. In: \"The Pink Sheet\" F-D-C Reports, Chevy Chase, MD, January 31, 2000, p. 20.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/32\">",
"      Kiatboonsri S, Kiatboonsri C, Theerawit P. Fatal respiratory events caused by zanamivir nebulization. Clin Infect Dis 2010; 50:620.",
"     </a>",
"    </li>",
"    <li>",
"     Tamiflu (oseltamivir phosphate) prescribing information, Roche Pharmaceuticals, revised November 2006.",
"    </li>",
"    <li>",
"     Japan May Lift Warning on Use of Roche's Tamiflu by Teenagers file://www.bloomberg.com/apps/news?pid=20601101&amp;sid=aaXFBeFgaXVE&amp;refer=japan (Accessed on October 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/35\">",
"      Weinstock DM, Zuccotti G. Adamantane resistance in influenza A. JAMA 2006; 295:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/36\">",
"      Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982; 307:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/37\">",
"      Monto AS, Ohmit SE, Hornbuckle K, Pearce CL. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother 1995; 39:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/38\">",
"      Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis 2011; 203:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/39\">",
"      Hurt AC, Lee RT, Leang SK, et al. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill 2011; 16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/40\">",
"      Centers for Disease Control and Prevention (CDC). Update: influenza activity --- United States, October 3-December 11, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/41\">",
"      Centers for Disease Control and Prevention (CDC). Update: influenza activity - United States, 2009-10 season. MMWR Morb Mortal Wkly Rep 2010; 59:901.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. 2011-2012 influenza antiviral medications: summary for clinicians. file://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (Accessed on September 23, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/43\">",
"      Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Updated recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza for the 2010-2011 season. file://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm (Accessed on January 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/45\">",
"      Rasmussen SA, Jamieson DJ, Bresee JS. Pandemic influenza and pregnant women. Emerg Infect Dis 2008; 14:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/46\">",
"      Mak TK, Mangtani P, Leese J, et al. Influenza vaccination in pregnancy: current evidence and selected national policies. Lancet Infect Dis 2008; 8:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/47\">",
"      Kwong JC, Campitelli MA, Rosella LC. Obesity and respiratory hospitalizations during influenza seasons in Ontario, Canada: a cohort study. Clin Infect Dis 2011; 53:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/48\">",
"      Centers for Disease Control and Prevention (CDC). Recommended adult immunization schedules--United States, 2008. MMWR Morb Mortal Wkly Rep 2007; 56:Q1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/49\">",
"      Ng S, Cowling BJ, Fang VJ, et al. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis 2010; 50:707.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. CDC reports cases 18-29 of H3N2v virus infection; continues to recommend interim precautions when interacting with pigs. file://www.cdc.gov/flu/spotlights/h3n2v_us_cases.htm (Accessed on August 03, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Information on influenza A (H3N2) variant viruses (&ldquo;H3N2v&rdquo;). file://www.cdc.gov/flu/swineflu/influenza-variant-viruses-h3n2v.htm#table (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Interim information for clinicians about human infections with H3N2v virus. file://www.cdc.gov/flu/swineflu/h3n2v-clinician.htm (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Case count: detected U.S. human infections with H3N2v by state since August 2011 file://www.cdc.gov/flu/swineflu/h3n2v-case-count.htm (Accessed on September 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/54\">",
"      Centers for Disease Control and Prevention (CDC). Update: Influenza A (H3N2)v transmission and guidelines - five states, 2011. MMWR Morb Mortal Wkly Rep 2012; 60:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/55\">",
"      Kumar D, Morris MI, Kotton CN, et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 2010; 10:18.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. Clinical management of human infection with avian influenza A (H5N1) virus file://www.who.int/influenza/resources/documents/clinical_management_h5n1_15_08_2007/en/index.html (Accessed on October 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/57\">",
"      He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/58\">",
"      Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus, Abdel-Ghafar AN, Chotpitayasunondh T, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. file://www.cdc.gov/h1n1flu/recommendations.htm (Accessed on December 15, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/60\">",
"      Tanaka T, Nakajima K, Murashima A, et al. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ 2009; 181:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/61\">",
"      Moretti ME, Bar-Oz B, Fried S, Koren G. Maternal hyperthermia and the risk for neural tube defects in offspring: systematic review and meta-analysis. Epidemiology 2005; 16:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/62\">",
"      Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/63\">",
"      Perelson AS, Rong L, Hayden FG. Combination antiviral therapy for influenza: predictions from modeling of human infections. J Infect Dis 2012; 205:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/64\">",
"      Ison MG, de Jong MD, Gilligan KJ, et al. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J Infect Dis 2010; 201:1654.",
"     </a>",
"    </li>",
"    <li>",
"     US Centers for Disease Control and Prevention. Questions and Answers for Hospitals and Healthcare Professionals Regarding Termination of the Emergency Use Authorization for Peramivir IV. file://www.cdc.gov/H1N1flu/EUA/pdf/Peramivir_Attachment_22Jun2010.pdf (Accessed on October 04, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/66\">",
"      Bantia S, Arnold CS, Parker CD, et al. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 2006; 69:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/67\">",
"      Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009; 48 Suppl 1:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/68\">",
"      Kitano M, Itoh Y, Kodama M, et al. Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques. Antimicrob Agents Chemother 2011; 55:4961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/69\">",
"      Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011; 55:5267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/70\">",
"      Kohno S, Kida H, Mizuguchi M, et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 2011; 55:2803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/71\">",
"      Yamashita M, Tomozawa T, Kakuta M, et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009; 53:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/72\">",
"      Watanabe A, Chang SC, Kim MJ, et al. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 2010; 51:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/73\">",
"      Kohno S, Kida H, Mizuguchi M, et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 2010; 54:4568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/74\">",
"      Chan-Tack KM, Murray JS, Birnkrant DB. Use of ribavirin to treat influenza. N Engl J Med 2009; 361:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/75\">",
"      Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009; 360:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/76\">",
"      Hedlund M, Aschenbrenner LM, Jensen K, et al. Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection. J Infect Dis 2010; 201:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/77\">",
"      Yu X, Tsibane T, McGraw PA, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008; 455:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/78\">",
"      Koudstaal W, Koldijk MH, Brakenhoff JP, et al. Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir. J Infect Dis 2009; 200:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/79\">",
"      Marsolais D, Hahm B, Walsh KB, et al. A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection. Proc Natl Acad Sci U S A 2009; 106:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/80\">",
"      Muratore G, Goracci L, Mercorelli B, et al. Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase. Proc Natl Acad Sci U S A 2012; 109:6247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/81\">",
"      Dreyfus C, Laursen NS, Kwaks T, et al. Highly conserved protective epitopes on influenza B viruses. Science 2012; 337:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/82\">",
"      Moss RB, Hansen C, Sanders RL, et al. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 2012; 206:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/83\">",
"      Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012; 205:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/46/22250/abstract/84\">",
"      Cowling BJ, Chan KH, Fang VJ, et al. Facemasks and hand hygiene to prevent influenza transmission in households: a cluster randomized trial. Ann Intern Med 2009; 151:437.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6998 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-22DD962998-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_46_22250=[""].join("\n");
var outline_f21_46_22250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BENEFITS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NEURAMINIDASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Efficacy of oseltamivir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efficacy of zanamivir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ADAMANTANES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69456256\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16530540\">",
"      RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ANTIVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Target populations for treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Definition of high risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Timing of antiviral initiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Choice of antiviral drug",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H398832\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Oseltamivir resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H847204507\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      INVESTIGATIONAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SYMPTOM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ANTIBIOTICS FOR SECONDARY COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      INFECTION CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      INFLUENZA ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Target groups for therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Choice of antiviral agent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/6998\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/6998|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/3/12349\" title=\"figure 1\">",
"      Peak influenza activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/6998|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/50/33579\" title=\"table 1\">",
"      Groups at high risk for influenza complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/32/14860\" title=\"table 2\">",
"      Antivirals for influenza",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22506?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39880?source=related_link\">",
"      Antiviral drug resistance among seasonal influenza viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=related_link\">",
"      Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5528?source=related_link\">",
"      Diagnosis of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/2/31786?source=related_link\">",
"      Epidemiology of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2599?source=related_link\">",
"      Infection control measures to prevent seasonal influenza in healthcare settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=related_link\">",
"      Influenza and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=related_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19640?source=related_link\">",
"      Pharmacology of antiviral drugs for influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39032?source=related_link\">",
"      Treatment and prevention of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=related_link\">",
"      Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_46_22251="Classification unstable angina";
var content_f21_46_22251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Original Braunwald classification of unstable angina",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Severity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Class I - New onset, severe, or accelerated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Class II - Angina at rest and subacute (no anginal episodes within the preceding 48 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Class III - Angina at rest and acute (angina within the preceding 48 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical circumstances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Class A - Secondary unstable angina (in the setting of anemia, infection, fever, etc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Class B - Primary unstable angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Class C - Post-MI angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intensity of treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No or minimal treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms occurring in the setting of standard medical therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms occurring despite maximally tolerated doses of beta blockers, nitrates, and calcium channel blockers",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Braunwald E. Circulation 1989; 80:410.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_46_22251=[""].join("\n");
var outline_f21_46_22251=null;
var title_f21_46_22252="MMRV febrile seizure risk";
var content_f21_46_22252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary results from Vaccine Safety Datalink (VSD) and Merck-sponsored studies for febrile seizure after the first dose of measles, mumps, rubella and varicella vaccine (MMRV) compared with the first dose of measles, mumps, rubella vaccine (MMR) and varicella vaccine (V) administered at the same visit - United States, 2009",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Characteristic",
"       </td>",
"       <td class=\"subtitle1\">",
"        VSD",
"       </td>",
"       <td class=\"subtitle1\">",
"        Merck-sponsored",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        <strong>",
"         Age/No. subjects, by vaccine",
"        </strong>",
"       </td>",
"       <td>",
"        All aged 12-23 months",
"       </td>",
"       <td>",
"        99 percent aged 12-23 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MMRV: n = 83,107",
"       </td>",
"       <td>",
"        MMRV: n = 31,298",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MMR and V: n = 376,354",
"       </td>",
"       <td>",
"        MMR and V: n = 31,298",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Postvaccination interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Week 1-2",
"       </td>",
"       <td>",
"        7-10 days*",
"       </td>",
"       <td>",
"        5-12 days*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RR: 2.0 (CI = 1.4-2.9)",
"       </td>",
"       <td>",
"        RR: 2.2 (CI = 1.0-4.7)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AR: 4.3 per 10,000 (CI = 2.6-5.6)",
"       </td>",
"       <td>",
"        AR: 3.8 per 10,000 (CI = 0.3-7.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Week 1-6",
"       </td>",
"       <td>",
"        0-42 days*",
"       </td>",
"       <td>",
"        0-30 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RR: 1.5 (CI = 1.1-1.9)",
"       </td>",
"       <td>",
"        RR: 1.1 (CI = 0.7-1.7)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AR: 6.2 per 10,000 (CI = 2.0-9.5)",
"       </td>",
"       <td>",
"        AR: 1.3 per 10,000 (CI = -4.5-7.0)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RR: relative risk; AR: attributable risk; CI: 95% confidence interval; %: percent.",
"     <br>",
"      * Statistically significant at &lt;0.05.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        From Centers for Disease Control and Prevention. Use of Combination Measles, Mumps, Rubella, and Varicella Vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR 2010; 59:4.",
"       </li>",
"       <li>",
"        Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010. In press.",
"       </li>",
"       <li>",
"        Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine 2009; 27:4656-61.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_46_22252=[""].join("\n");
var outline_f21_46_22252=null;
var title_f21_46_22253="Increased motor unit size in ALS";
var content_f21_46_22253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F65950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F65950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Increased motor unit size revealed by incremental motor unit number estimation (MUNE) in patients with amyotrophic lateral sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 314px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Average single motor unit size in a group of ten ALS control subjects receiving placebo in a therapeutic trial, as measured by multiple point stimulation (during MUNE assessment) in the thenar muscle group.&nbsp;Patients were tracked at&nbsp;one&nbsp;to&nbsp;two month intervals over 10 months.&nbsp;Note the steady and dramatic increase in average motor unit amplitude over time (more than 100 percent&nbsp;increase in less than one year), consistent with aggressive collateral reinnervation.&nbsp;This increase in motor unit size in ALS becomes especially pronounced as the MUNE falls below 50 to 100 units.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Clifton Gooch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_46_22253=[""].join("\n");
var outline_f21_46_22253=null;
var title_f21_46_22254="Acute HDV in chronic HBV";
var content_f21_46_22254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Serum markers of an HDV superinfection of a chronic HBV carrier",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 370px; background-image: url(data:image/gif;base64,R0lGODlhSQFyAfcAAP///wAz/wAAAP8AAJkzAGYAZgCZM2ZmAAAzZvzy8s8/Pz+yZeWZmdVZWQ+fP8zMzL/lzPXZ2e/58n/Mmf8REdllZYiIiA8/b//u7hFB//LMzJ+fD+yysvn57/Xv9cWfxXkfeczMf99/f28Pb9/y5VVVVe/y9bJ/sp/Zsv+IiDMzM5+yxREREX+Zsh+lTNm/2fjx7l+/fz9ljMwzM+Xlv8+giP/MzLKyP7i4iC+sWYw/jM/s2c/Z4pmZVZ9fn7/M2d/l7NnZn5lVmbiIuL+/X09ylXARcP8zM/9VVZmZAOzsz62td+7u7i9Zgl9/n9JMTPXu9fLy3++/v3d3d+748W/FjOLP4oIvguKMjMmSd/nl5aWlH6ysL1W7d8+vz6/fv9/fr4+lvLt3Va+/z/9ERP+qquzf7ODM4O7x9eDgzJVPlURERKqqqtxycsyqzP8iIlV3mR9MeRGgQevWzO7x/8zMqoUzhbm5T6BBEalvqYiguIjPoG+Mqa13remlpYWFM6q7zKrdu8zr1nBwEd3d3d27qiIiIryPvI/SpXfJkoig//X17k+5cneS/9LSj7RpRK1cMyKnTsXFb2ZmZqdOIneSrXoiev93d1V3///d3Zmt/5+y/6q7//8fH9/l/3p6IvHk3RFBcI+PRM/Z/z9l/8zW/yJOeo9Ej/+Zmf9mZuvr3f8/P3+Z//+7uzOtXN3x5JmZmWaF/8LCmaOjZkS0ada71mbChcKFZv8PDyJO/zNc/9bWu/9PT8KZwg8//9atmf9vb7u7u/+/v/+vr//Pz+/y///v7+TJu/+fn19////f3+vd65nWrURpjzNchd3k693k/6Nmo7/M/7vkyURp/5JqfL9EPb2uetSGgZqLJ6+cYs4+PpPInpmHJj+EPMdscdFiX7vJ1sQ2OKSNTaYzPLJLPZeSB89UVYw9TZmtws3Fk6ZGMzhWfSYzXEKdVI+CXQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABJAXIBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3qhIaQUJIunEjSZK6gJvSoBEiBF+/W27cKTy4Q+DHQqPQcBTiTt8kXG5ICgGGhmPIoAeaefHiw4nTJ9ToWM1aB+rTpF+QlEz5BpckG24QCRHEc+jfAKx4OeFDx4gCI1aref0hduzhqPOsBlGgwBUdeU68sGKRBpjKfXPv/+4MvLwZL9ILgHB96IWZjaRPSD9+xUf7hXgNb0mSmLfv8uV5gB51rr3gwUkevHCID1dY58MHZkTx3R37bbEYeQBmCIAHH6hhnXYx0XDNON0kYU422qhDg4YrCVHAGVVx6KEaHxzo0mRE3GZhCJ5ZcYiHV+TBHYsnuQijQWdUN4RAlhTQh0QuugEAFAUYYVCUU1YHxRDVVSfEMgCcUkAvAom55EJW+JBcjS0pEUSOmBHhyIoJDTiCD14QSZKRByVZgCUAcOkklAVImRCWVBaw5aBuGGEJFL0UcMqURhgBhUIfXDFCHu+p1MF3fe3430NW5AHCnXnq+RGfLlZZaJJGFP8whCWxPjmQoH9KaUcBrQ6Bqx0AVHploVkqyqWtfcgarKVcCoGQByeAcMUHKkXx5m2agRFFRqWCAAKnqnJkZLMARJmkHS4acexBXE66ay21VFkuscsmWgCwrXZp7KCBDhqNrO8aBG1ysp1kLRFb5MZjSC+oOa2N4VpkpItLmntvktGsO5AbYlYH7K5nUGkllssOK2WiiyKrbLxNAkrQwDoUTFIHbyZ8hyNKIJjppp1GPNG4g4rpxrm38itQrLUQDbLI85JZckGIarluo48yqSRBH6wns0g0SIJtCDm3lGYBamzts0NGQiGmEbsOfW/Rtgok6K4fv8j0GbECKyzUxKL/jCuvl8pdHZgAvHAFCGZ7RPMdG2whCRg0DTzt2RVB0SThPHmg5gkiReHIbTdvm1PWIFBLuUP2GuE0T16MoEbPHUURAhcbEAHGZz2RbvrpTHmgBgipxv557ZATRXrwvB/Veh4Qa0RzX7YrlXXMyRel+QjIZ6QEEbkFgbtSA/sAe/U9WXFd8xfRTLskokNlhpqHkO/TByNw7nwI3V/1grRDyo+TmomjSBSIkAQi0CkrxPHfTTxwhSugT4AEJEL7FOg/K4DABxnpQAgKOEEKyu8FI4gfRvB3hw56kHwfKMDuKkKDxBzwhP6jX/8EyLggwNCDaprhRByxAUl874bk8wEI/3QYESVwgQsvBGIQHWgRRyQhBEqkIIMe+JAo2CZsUZTfFCsChh7+MIu82+JEOsC94oGRfIcYAREdEoXMfPGMlJMhRbooCTjKT44TwZ8Z7cg7K2BvjDnCIh9PZ4YRrPAhHXDjIJPHwDxMRAlbIMIiq6cDNTxyA46YZPLywMSIBCEJNtTk6eg3voYEYQNJFGW4/BjAhZxSkKoMlwdAYD+I4A+WsVSVGiwZEe7hMpdEOgQIqKgQXwLTZ1YowBqLuYFfHjNDDKylQ175zIhJx5PNrGa4WldKhVBTm3rywB8f0kVnghM4u4SIEjYQynOyqHXEPMg62+lOaI6zIYmEYj1ZlP9OhyRSkvvUEAjjaZAcBVRDszykQkKwhTceFDIn0AE5s/nQ8iSzm/LcwB4rGhrX+JML+uTob7JGUILc4Q4iBc4ss5cQhjo0pXSJqENoQFGYQsYMysQnO20aGh9gsCG64SloBtqQ2b1UqHDxKEOUkARzIvUt+yspADqwhUw+NTCla8herhqYrDWki0flKluyupAOaFSsdfEqQ05qkB4cIA1oHatCDQLWtr4VIYuYxQEO8IclwDUigzjAIgCwhAPgoCBp4KtACrsEALh1rwdoLAACqwqBBPavcRWJWhVi1o0KxK2YLcgnBiELACyiB4cFrGATktg/LDayjj1AHQCAgwP/iAIAej1sHRSb2ZGQVSFsPQhoY3uAwNZBFgeYRUIea1tV7PYPf+DraSG7hNqmdiCtfW1j3TpbAER3F7tQrFuv29uPbDYhNHUoaGvbg9jWobDkRch4d3tbURh2squ17m736lfIUte9n5UtAD5xgF0MYhDlFclvEUJVehYEtON1L3JnsQjIkhcHBObvbtsLX/wO1rqI5S1jAezdu9aWwMpNsHlBwBDDKGS9sLVvHRZB4NJ2WCCJRXBtl7Bhwt6XsrS9L0Gy6+PtCri2twWAKiC7CxV/RAdzJQhTTUgQ0C7CvoOI7mxVwdxPhPax0eXxATh839pGFsRDFjFsmStkgdj3/xNO9ggIGXKDkDqExgeobJyxshxXNvTOkCXtnrFSSIJ2dtBs8elCtopotYgTowKJQhKo3OixHEKiCqlzpdUCPIWkd9No8QKLFbIFB4N6LGoQIUKCsIVTnwWn8aRqKl0NlgS29Aa0NgviEmLWWee6K6JeKK5/jWpVG8SslCa2VjxQAEiHAKDKBkuHEiLpZEcbK5NDyLOvDZZC8noD1uZ2VRbUUmiLmyudPohZnXruqfjx1u3uSh5+epAt+DreVEm3QYLABXxvxdsIKfUkPVGMG5L7IC3U5CgCkIxRnBDKCNmNKEkRgACQYhNSJOakRbmJilfcF6zwxE1Y4fGSm/zkKP9PucpXzvKWu/zlMI+5zGdO85rb/OY4l4a/vdJxj4Nc5DvvCsUtjvGge2XhDTc6WAiu9KY7/elQ9zcnTl6KAGQg6lahg9WxrhWtX10gGbh6IwJAjQwEIBaYsHopAKCJXFQcE1wfitcHEnYAjF0RADA7NDRx9qrrAgCxCIAm4h6UuYNd7AHAu9npMHVMKMLkjSA8UAyfd8QrPgCMDwAm/C55uW/98HZPfN4x33i2u73ieO+86lfP+ta7/vWwj73sZ0/72tueqwOATO4HvfvA9D7Ov69L8FU8/LkUv7zHj0vyM7v8tzQfrc9vS/Rxr3tEH58YZ8H+QaZ/1eAbAxmd4MX/WXjRCWQYoyDcf2rvlQEMXAxgAMI4izDejwtgKGMg6Udq7oexive/vxNp0Qn+NwCrMAwAkH9xIQAKuIAM2IAO+IAQGIESOIET2H8DeIEYmIEauIEc2IEe+IEgGIID2H8UWIImeIIoGIEAsn8W+H8BOIIGiIA8tX7t937xZxbzNwD1d38CIYM25X3gJ35mQX7mh37WhxDaVxZJaIS8V31N+Bg+CFNRSBZTKFJVKBZXSCRTIAAWcBEPIAAlYBHNhwEDQAEpgQQDYAMEQQZHQBNoWAY92BFb2IUW8YVhmBRMwAICsAYDoYdMIBBM4IB0CABz6IVgCAAqIAAPIBHBhwEU/zAAZCAQZGiGKIGGaigQNjAAKQAAl6CJMPGGcVgQebiHfSgAfwgAgdiAg1iIdXiIibiIRWEBC0gIAuGHBfGKBcGKFWGHYlgQKeB/mQAAk3iGaTgQl0ABGOCGAwCHB2gQsqiAtAgAtkgQuEgQukgRvJgUiZiIU1CLpniLipiLe6iHkwAAzygAhsAGAAALeigALAAAD7AGCrgGhMCLJaCIbCAAKrCNf3iOgxiKA3EEAyCQlyCMZUgGA/AGNjCJCEkBamgDAgmJmcCQA0CRb5ACbzAASAAAv/h+bwCHljgQb5AKAvGLKUCRDgkAqJCRA0mRGLCS77eRHZmQcIgKj1iGAP9gAwgpkQCQCu/3iMw4fNsoAN0ojd9IjeFojeMoAOV4jum4ju34jvE4j/V4iPf4APm4j/rYjwv4jzTxhYYAlt54igNRjQNRiIkYDAMhi2sQiCwQjQBgCCzABLDAlPaIj6QojxYgi91oCAIAlwaRiQqZkAZphmUAicP4ixv5BsjYCi05gIk5ACSZkcFYkpAIACEJAIfZCpZ5kjipmJl4BMlokP4Xmj05AKgwEL9IBpNYmQDAmC8pmYqJmcuIEGAplkZJlgJhlgKBlgKglgLBlm4Jl3JJl3ZplXjJh3rJl3H5lzcxCQ2ojtNYlkl5llwIAPfIBmwgjwqoAgAAnQpYAl//yIAqcJdYeYhzeI8MqI4I4ZMDWAbDGJrDeJhIYJpkWJE4WZgcOQAFKZA2UAY7OZC0eYlI8AaqqYnzqZG/WJCSmJ8z+X6XAKD+14buqZGZOIBH0ImbCIoHAZ4LKJ1HSZ2waJ1dmJ3buYDe6aHi2YDliZznGYbpGZ03oYeLyJa5CY4j2ptcyAR++QB6GAxf6J2AqIeEIJdwaZ75CKNcKIvlyBCPqIarGZlIkKCL2ZiPSYmR2Z9p+IitYJohmQme2JlUKp8NSommORBceqbC+IiZwJiuuaAAgJDMaBA0ao6kOJ27WZ06agE8qog/GqQDMYpF+pYDgaTouaRMqROyKKSC/9qOCkiHvEmIDAgLdqqP+jie7tiFUxmehqqkXXiOekoQv9iGa5qGA8iaVJqTEUkGE5mfWQoA/tmRAtmGIZkCyHignmmYGqmSLCma+cmr/pcCsjqQF1qGm6iT/reRDSmQc0oQizqkf+mo14mIobqFC0ipz7iNmMoCmsqdYNipkvqpDJijMPUGG3l7RuGYzYqu7Nqu7vqu8Bqv8jqv9Fqv9nqv+Jqv+rqv/Nqv/vqvABuwAjuwBFuwBnuwV9EFBhAIAEAFBmAAVLAHD/uwXfAKACCxtiAQEtsFBCEHE2sAiQAAgvCwIRsIBsCxDeuxtDCwCsuwDguxEluychAJVPAKBv8gBwLhCgvbsRALAJFgAIIwsg8rCCaLshL7sBYbsC3bsA8bsSArEIlgAHsAALSwsCMbCQXhsVRABZEgB1RwtQbgCkWbs2H7tLa3AxCQtmorARChsB8Ls2YbswDADCcbtVPLsw8rB4IgsidrCwZQtRx7tVcreySAAjGQAwbgAguwuIz7sAsQAyhAAguxtC/rtCELAHYrEHIwswaQtAOhtT/LDHzbBVxLsQDgtx/LsK23A1XgAg7ACIgAAQkhARAwAYzgAC5QBbJ7EJTbtHIbCDNLBQKBuiubtRA7DTf7CiPLsSZ7sgDgsXsrscXbeRKAAjngALorEazrArkruQTRu3D/O7GkOxDIawCia7zCG7WusLwCobBdILGuIBBU4LGey3USMAEOsABfgBE7EAP5iwIIixD36wAx4L0aUb3cOwFsG8ACgQL5a8AeAQEL4AAKjLAksAAusLsjIcEUvMADiwgGMAEpIcEuAMABKwELkAM7wBIooLgazK87QMAezBL4GwMzjK8oYAAmDBMkcLs7fK9V4AArTBNfoLgQPK+HO8QPYQJjwAcycAEIEMUXUAQrYAIHHMSIwBRiQACFAAAwQAAEAAM1AMZg/AgwgBAwgAcE8AiTdLg3rBBAEAZNgAAy0AJjwAMDAQQrUAQX0AIbAQFGrBRb3MVfHMZjnAUAsMU1/4AQYwzGoDBIbuwQP8DHTjAGCwEERRAHeJwREnC7+4sUg+zFYCzGBIDIWzwHAPALakwAeCAQkEAAr4zIANDIaizLMBTJDPEDMhAHVfwQK3ABK7ARXyDDR7HFZDzKjVzGc/DFePDIAjEHBEAJ0EwJADDNs1zKN4TLcLzLwSwRPADMG0ECOaDCRhHKhUzKiGzNt0DGYgAA63zMhTDG7XzIMFQFOfDGBtECCNACVkwR39zNGoG/PxwU5ozM2HwM0TwQaUwAoKDGqDzGj4DQkHDNtqxADnzEBgEETdAEQIAR/8wRwxwDRFHQhnzMjzAH0AzGeFADYzzRXqzGoJAFYBzLHv8EAUK8EGPQxxvBAwiwyRohzjmA0V3xCATwCxQUwwOdzxfwAx2xAnHQzxvhv0rMFa8MxhVNPhKQAyKsEE7QBD7NEUVQBB6Rw0kteTGwAAvR1VDdESYQB5bcETYt0quHCC6AzwOh1iKR02utETuQA4xg102hAYI92ILdEyRNymRsxmisxmy8EzH8wgaB1yNRBHzwESh8z0mhBRrgBwwgAhVQATMQ2jPQAJ9d2hXwBKG9E4dNz4rMyGTszDmh1VzdBHsNEkBwAV/NETHgAlPtE1ogBQzQBg0wAwpQASLAAH4g2AkAylwsyiVtygSAyqqs0q4My9h8zax83TBhzwrxyx3/bRItIAMhgb+9jRMaENwKMAMVgAUcoAFRYczHjNjKzMywPc3WbM30DBM2LdQC8QO4bRBwgACAAABoEMVooAdRHMVw8AwDAQhRrAcMYQJLHRIO/Mk2cd6g3QDsHQFWsdrYrM7s7M7HzMXyTNEwIQEukMUIcdsATRABPuAFjgAHjgCVAACAEAqmgAYCEeAIYAoNsQLiTeEhDNgpoQUc0AYz8ARYIAXLnRUejsgITc0CsdANHd3XHNGwbOIvMQFonRBNUNkH8eIEbuAIXuMAUAkIAOFoEAqh4AwCvuNRHApvThBuLRI7gMGQXeR+MNxtwAFa4BUentgoTcYr3dJTDtMy/23dV60SO2AA/A0ALdAECcHjCS7jZS4Ql47gcKDpAMDpYk4QQE4SiPC6RP4RWrDnCiACUkAkRG3ULrEAW30Q/v3dYf7mMT7jZo7mEG4KlR4KaBDgEP7pBDHhI9HJDqDiJHHkM9AGq84iVa3dLOwCCdHWYaAQYn7rl37jOR4OPQ7nenDpzTDnBBHeJgHIC1DeG6EFWKAADcABTV5REuAAeT4QTrwQ107mlQ4HOh7gZu7gOR7ubS7uAyHhtF7sE2AAVVDqEiEFFZDqHO4Vgs3ZDDDxFD/x7e3eTFEFXS7rF1DwIoEGvM7gke0EKHHBLmDhFpEAHPAET+AH744VCQDcDf8/2sZd8TbfBqdN3BXAAFLw50VBAo7u5dU+EjGOAKGQDit+AbU9EsO8AI/OEAnAAMXd7Fyh3jz/8A8RATKvAE+g6i/vE4xQBQkhxzQhA0OPEhJQBUMeEVFf3BgPGRHAAHzu7j5h03Yt4Uw9E07NEnd+8g7R9hXw9sCh8g0vAoKPE7CeEE4g1jVB7CvhwE6/EBzg9qqi7uzOATlh9yuOAB4fE3xA8i1xvwiPzxrwBA1w+Kqy8k+A+TaxAGUtEJR9E9+89CU/wT+sBQ3P+ryj+lQfEy2cEP5N+zDRBC3eEkW8ABAQ9TPAAF+/+09QAT4PEyWcEHWcE2HA+DExAd5gDeD/EP3+o/wMoN/SjhDBnxNAgADCjxIJgAXb8A4dfEIR0AANgPUr4foJUQR+rBNUDBMRABBPKiQAsGOBCxQAFC5k2NDhQ4gRJU6kWNHiRYwWGczwk9FjRAgOIgK5YOLjyZMriqBkyZCBgo4Mv7jIAaHlTZw5dd6M8KQNwZ0VF0yI6MRJUKQATCAwmZRiggoNIkCc4GABCadZtW61mKCNVK4MSTiQABEIAiBhbxZZobZhTxFAIUqYYCAGVrd59ep8OVVtjCoRWxzd+1HlXg4wLZKI4WBC2cKRJVvkMINDWBIG8D688GMyxrNN1b7UkJHEAseQP69mHUHB5a0TYkRc0YT1/8UmbdWKAPsRAurHt4VHdg07qwObEHMPpxiG8FavDeSe/I1QNXPsWotnRZEjIo+S2b9f4JqgwcCcv1OLZ490e9IFCSEabQ8xjues5kUgVR+8/n+W3ttpB7IiuoAHABvig4/8GtjPKQhisGuHBCvESAoF/NIphtkgqs3ChcawLSn9uCKhCqtQuA5EFhlKTMObJHCAQoiKCKNFANBCqkS1JOjOgRi+WBFHCxmQLqfuRmIKRxl004lHvUhAJAcDcmBkggkg0BICGsXa8ksssaxiATKpNIDIrUSoIKf4IgpjJRyd2wlKySBARDYyyzRgTz6tyjPPKsLMcks0y2sAi5vGGv9yoeVwBO9JBwuVVDItXmupig4fCg3NA3P6alJQC9MgQ5Zc+MJNOIm0ESfepgv1Va6MdPUiCFyQqFEi37wJiyNh9TWsNh70CDAlRXOUPJZe/HVZ6J4wDqMZUZ2005OUZfZap0aFsaKZJGpy0lU/ck0KbMtNSlaMYkAkoqWMzTVVjAQ0d96cKkD0Igc2c+jDSR/NyLx76RX4pkrJ5da7om4EldqLIh344ZYwnPUhdSViWFK2MGoVYo5RUrOifL+L49XBLuJ14o5TniiBJ2KK6AuEISo51B9GrshalXO2SFuJYiAqoibGgHXJiTSYYVudk47ISImihahdWGUQWiJ5lbb/GqJDIdrB1ohE9JWPFiRKQLGry4ao0tIcqiKwiBb0dQwZIqLTbLoX8uOJWU29Fb9Xz4Jo7roDb6ONhsaSaKllL15o48AbV2jsZxFhRCK4l/22IcYdd5xnhRiRDyKwl22BQYYy19xxXhfS7Napff0h7oX6On12ALKGeSKifUVcIZxpd7zgtSX6YcRl40Cwd98dx9Cd5GR+7le2kE/ecWzWQVmhjJltoRpSp6cdhXKE5QxBZr8RB2nvG4+BG0s1RXZZEc5pJ33fXdghghnSbqjyX6NLQHH61c1wAJBeC8LmK/OgR2oB1BwKJqeQkzVkgbByjbAMyEDHVWxxvVLIBdLy/6rEPGsFsMNg3ezHECiR5FUJEIEC9KcQHtishGYbIAodxr9JReA8E8vdDK2GggU8pEQXnJQfFMAAoPHNh0oL1N8clD00aaECT0DfQpygsCUqrSZyawA6yEekjTDgegoZXRaVJoEziY0cHASRBgRSxYa8zoxJg0DMIPIDdvAGjuLRQAXaVxEVzjFnE2AbbVbyEoP9RwstFGNGeihIiLVJIkTEUMD46MdGekQGSoTkw0LmrdZJsTfM4UADjjjGiVyxkxyrYUSM1xAjYgGVbokAFhTQgGedpIyrfNgXgoi7h2ihDUecTC2foAAs7BEjcuTlwLA0kRhGpI9PyGRYEiAFLP8cUwSJzAkQZNjMeS3gVJQjIUQ0MEwRKJMlWsBmBWbQAAaoEyUIAKfAPimYA05EC9l8AhakMEuKaIADDJjiDCrAgH9ypQmcrOeyWjkfLFYkAgR9pwgYoAENaOEhEcCoBvzAAIL68Z1tQKg8d1KE1jWUWb6kyCZP4tGQKmAGM6XpDARSgQpYFKEZ/QwRVcqsZ07klQNbwfN+6itxUoSeD2PmUX91Qol4E2ImeJ9TYZVG4ZVTYEu16qvqSJGicsylXQ0VCjKFT46hlKyhCqpE+BBRgfl0rYVK6kTG+jA5YcsTxeAlVL3F0Hk1lVmjCEAyRtFJrErkkfSKZrlIEYAAkGL/E13lKsQqy6xNQBayvmCFJ7LDCs2GVrSjJW1pTXta1KZWtatlbWtd+1rYxla2s6WtNOZ6W51kVrOc9SxufduSx0Z2sr8lLkoIa9jiJvcke1Vuc537XOhGV7rTzSInRluKAGSAutGlQ3a3u93ualchGdBuIwJAjQwEIBaYyG4pAKCJXEAWE989angXQl4AmFcRAEgvNDShXuzqAgCxCIAm6KtS+463vAHYb3rpYF1MKEK0jThwQxPM3wU3OAAPDgAmAlzh+npXwfllMH83DOH3xhey+wVxi138YhjHWMYzpnGNbXxjHOdYxzvmcY99/GMgB1nIQyZykY18ZCQnWclLEGZyk538ZChHWcpTpnInAwIAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The serologic response to acute HDV superinfection in a chronic HBV carrier must be distinguished from acute HBV/HDV coinfection. HBsAg is present in both situations, but IgM anti-HBc should be negative in acute HDV superinfection. The diagnosis is made more difficult since HDV superinfection may cause transient suppression of HBV replication, transiently resulting in very low and rarely undetectable levels of HBsAg. As in patients with acute HBV/HDV coinfection, patients with acute HDV superinfection are usually positive for HDAg and/or HDV RNA in serum at the time of presentation. However, in contrast to acute coinfection, acute HDV superinfection is characterized by persistent detection of HDV RNA in serum and rapidly increasing titers of anti-HDV (total and IgM).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_46_22254=[""].join("\n");
var outline_f21_46_22254=null;
var title_f21_46_22255="Management central obstruction";
var content_f21_46_22255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Algorithm for the endoscopic management of central airway obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 486px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Rigid bronchoscopy preferred.",
"     <br>",
"      &bull; Careful airway evaluation and airway computed tomograpy scan, &plusmn; flexible bronchoscopy, &plusmn; endobronchial ultrasound. &plusmn; autofluorescence.",
"      <br>",
"       &Delta; Possibly with presurgical endoscopic intervention.",
"       <br>",
"        &loz; Silicone/new hybrid stents generally preferred.",
"        <br>",
"         &sect; Can be used singly or in combination, may need stenting.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ernst, A, Feller-Kopman, D, Becker, HD, Mehta, AC. Central Airway obstruction. Am J Respir Crit Care Med 2004; 169:1278. Copyright &copy;2004 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_46_22255=[""].join("\n");
var outline_f21_46_22255=null;
